325 results on '"John R. Vane"'
Search Results
2. Comparison of the Haemodynamic and Platelet-Inhibitory Effects of Endothelin-1 and Endothelin-3 in the Anaesthetized Rabbit1
- Author
-
G. Roger Thomas, John R. Vane, Christoph Thiemermann, and Paul S. Lidbury
- Subjects
education.field_of_study ,business.industry ,Hemodynamics ,Medicine ,Platelet ,Pharmacology ,Inhibitory postsynaptic potential ,education ,business ,Endothelin 1 ,Endothelin 3 - Published
- 2015
3. Bioassay-Abenteuer auf dem Weg zum Prostacyclin (Nobel-Vortrag)
- Author
-
John R. Vane
- Subjects
Chemistry ,General Medicine - Published
- 2006
4. Recent Advances in Prostaglandin, Thromboxane, and Leukotriene Research
- Author
-
Helmut Sinzinger, Bengt Samuelsson, Sir John R. Vane, Rodolfo Paoletti, Peter Ramwell, Patrick Y-K Wong, Helmut Sinzinger, Bengt Samuelsson, Sir John R. Vane, Rodolfo Paoletti, Peter Ramwell, and Patrick Y-K Wong
- Subjects
- Neurosciences
- Abstract
The International Symposium on Prostaglandins and Related Compounds, first held in Vienna 1972, revisited the city after 24 years for the 10TH Symposium. For the many re searchers working in this multi-disciplinary field it was an opportunity to exchange their ex periences and share new data with colleagues from all around the world. This scientific exchange was largely encouraged by the unseasonably cold and rainy weather. For the first time, there was quite a large attendance from the former Communist countries. Eugene Garfield prepared a key note address delivered during the meeting (The Sci entist 1996, 12) reviewing the contribution of the Nobel Laureates U.S. von Euler, l.R. Vane, S.K. Bergstrom, and B.I. Samuelsson, discussing the relevance of the more than 40,000 pa pers in this area published since 1991. Overall, there is still a rapidly growing interest, and in particular a great variety of clinical applications of this family of compounds which were dis cussed in detail during the meeting. Beside the lectures there were 19 workshops covering nearly all the topics of key in terest. All the speakers were invited to prepare a manuscript which has resulted in the volume now in your hands. Special thanks to Dr. Patrick Wong and the new publisher of this series who helped to publish the proceedings in the usual quality and reasonable period of time. Looking forward to seeing all of you again in Florence in 1999, hopefully with much more sun.
- Published
- 2013
5. Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs
- Author
-
Daniel L. Simmons, Regina M. Botting, Matthew L. Madsen, Philip M. Robertson, and John R. Vane
- Subjects
Diclofenac ,Drug Resistance ,Apoptosis ,Pharmacology ,Monocytes ,Mice ,COX-3 ,medicine ,Animals ,Enzyme inducer ,IC50 ,Cell Line, Transformed ,Multidisciplinary ,biology ,Chemistry ,Anti-Inflammatory Agents, Non-Steroidal ,Membrane Proteins ,Biological Sciences ,Enzyme assay ,Acetaminophen ,Isoenzymes ,stomatognathic diseases ,Cyclooxygenase 2 ,Prostaglandin-Endoperoxide Synthases ,Enzyme Induction ,Cyclooxygenase 1 ,biology.protein ,Cyclooxygenase ,medicine.drug - Abstract
The transformed monocyte/macrophage cell line J774.2 undergoes apoptosis when treated for 48 h with competitive inhibitors of cyclooxygenase (COX) isoenzymes 1 and 2. Many of these nonsteroid antiinflammatory drugs (NSAIDs), but in particular diclofenac, induce during this time period a COX activity that coincides with a robust induction of COX-2 protein. Induction of this activity requires high, apoptosis-inducing concentrations of diclofenac (>100 μM). Prolonged treatment of J774.2 cells with lower doses of diclofenac inhibits COX activity, indicating that diclofenac is a time-dependent, pseudoirreversible inhibitor of COX-2. It is difficult to wash out the inhibition. However, the activity evoked by high concentrations of diclofenac has a profoundly distinct COX active site that allows diclofenac, its inducer, to be washed readily from its active site. The diclofenac-induced activity also has the unusual property of being more sensitive to inhibition by acetaminophen (IC 50 = 0.1–1.0 mM) than COX-2 induced with bacterial lipopolysaccharide. Moreover, relative to COX-1 or COX-2, diclofenac-induced enzyme activity shows significantly reduced sensitivity to inhibition by diclofenac or other competitively acting nonsteroid antiinflammatory drugs (NSAIDs) and the enzyme activity is insensitive to aspirin. If the robust induction of COX-2 observed is responsible for diclofenac-induced COX enzyme activity, it is clear that COX-2 can, therefore, exist in two catalytically active states. A luciferase reporter–construct that contains part of the COX-2 structure and binds into the membrane showed that chronic diclofenac treatment of fibroblasts results in marked mobilization of the fusion protein. Such a mobilization could result in enzymatically distinct COX-2 populations in response to chronic diclofenac treatment.
- Published
- 1999
6. Selective COX-2 Inhibitors : Pharmacology, Clinical Effects and Therapeutic Potential
- Author
-
Sir John R. Vane, Jack H. Botting, Sir John R. Vane, and Jack H. Botting
- Subjects
- Pharmacology
- Abstract
The mainstay of therapy for rheumatoid disease is the non-steroid antiinflammatory drugs (NSAIDs), despite their inherent gastrointestinal toxicity and ability to cause renal damage in susceptible patients. The theory that the beneficial and toxic effects of NSAIDs stem from a reduction in prostanoid production through inhibition of cyclooxygenase implied that particular toxicities were inevitable with NSAIDs and would always be correlated with efficacy. However, over the years, it became apparent that at therapeutic doses, some NSAIDs had greater toxic side-effects than others, a fact not explained by the general theory. A significant clarification arose from the discovery that there are two distinct isoforms of COX, a constitutive enzyme (COX-I) responsible for the production of prostanoids necessary for platelet aggregation and protection of the gastric mucosa and kidney; and an inducible enzyme (COX-2) that is newly synthesized at sites of tissue damage and produces prostaglandins that manifest pathological effects. It became clear that different NSAIDs had greater or lesser effects on COX-I when used in therapeutic doses, explaining the variation in side-effects.'The elucidation of the crystal structure of these different enzymes and the skills of medicinal chemists have led to the synthesis of new chemicals with a selectivity for the inducible enzyme, and thus with therapeutic efficacy without those toxic effects result ing from inhibition of the constitutive enzyme.
- Published
- 2012
7. Improved Non-Steroid Anti-Inflammatory Drugs: COX-2 Enzyme Inhibitors
- Author
-
Sir John R. Vane, Jack H. Botting, R.M. Botting, Sir John R. Vane, Jack H. Botting, and R.M. Botting
- Subjects
- Nonsteroidal anti-inflammatory agents--Physiolog, Nonsteroidal anti-inflammatory agents--Side effe, Cyclooxygenases--Inhibitors--Congresses
- Abstract
In 1971, Vane proposed that the mechanism of action of the aspirin-like drugs was through their inhibition of prostaglandin biosynthesis. Since then, there has been intense interest in the interaction between this diverse group of inhibitors and the enzyme known as cyclooxygenase (COX). It exists in two isoforms, COX-l and COX-2 (discovered some 5 years ago). Over the last two decades several new drugs have reached the market based on COX-l enzyme screens. Elucidation of the three-dimensional structure of COX-l has provided a new understanding for the actions of COX inhibitors. The constitutive isoform of COX, COX-l has clear physiological functions. Its activation leads, for instance, to the production of prostacyclin which when released by the endothelium is anti-thrombogenic and anti-atherosclerotic, and in the gastric mucosa is cyto protective. COX-l also generates prostaglandins in the kidney, where they help to maintain blood flow and promote natriuresis. The inducible isoform, COX-2, was discovered through its activity being increased in a number of cells by pro inflammatory stimuli. A year or so later, COX-2 was identified as a distinct isoform encoded by a different gene from COX-I. COX-2 is induced by inflammatory stimuli and by cytokines in migratory and other cells. Thus the anti-inflammatory actions of non-steroid anti-inflammatory drugs (NSAIDs) may be due to the inhibition of COX-2, whereas the unwanted side-effects such as irritation of the stomach lining and toxic effects on the kidney are due to inhibition of the constitutive enzyme, COX-I.
- Published
- 2012
8. New Targets in Inflammation : Inhibitors of COX-2 or Adhesion Molecules Proceedings of a Conference Held on April 15–16, 1996, in New Orleans, USA, Supported by an Educational Grant From Boehringer Ingelheim
- Author
-
N. Bazan, Jack H. Botting, Sir John R. Vane, N. Bazan, Jack H. Botting, and Sir John R. Vane
- Subjects
- Pharmacology
- Abstract
For the past 100 years the mainstay of therapy for rheumatoid arthritis (RA) has been aspirin or other drugs of the non-steroid anti-inflammatory group. In 1971 Vane pro posed that both the beneficial and toxic actions of these drugs was through inhibition of prostaglandin synthesis. The recent discovery that prostaglandins responsible for pain and other symptoms at inflammatory foci are synthesized by an inducible cyclooxygenase (COX-2) that is encoded by a gene distinct from that of the consti tutive enzyme (COX-I) provided a new target for therapy of RA. A drug that would selectively inhibit COX-2 would hopefully produce the symptomatic benefit provided by existing NSAIDs without the gastrointestinal and renal toxicity due to the inhibition of COX-I. Drugs selective for COX-2 are now available. Experimental studies have shown them to be effective with minimal toxicity, and in clinical trials gastric and renal toxicities are less. Highly selective COX-2 inhibitors, perhaps designed with knowledge of the crystal structures of COX-I and COX-2, are also available. Other experimental studies, including those in animals lacking effective genes for COX-lor COX-2 and in experimental carcinomas, suggest there is still much to be learned of the pathophysiological functions of these enzymes. The inflammatory response is a complex reaction involving many mediators that derive from white blood cells, endothelial cells and other tissues. Preliminary data have revealed that inhibitors of the cytokines and adhesion molecules that play a crucial role in the migration of white cells to inflammatory sites may be useful in RA.
- Published
- 2012
9. Mechanism of Action of Nonsteroidal Anti-inflammatory Drugs
- Author
-
Regina M. Botting and John R. Vane
- Subjects
Aspirin ,business.industry ,medicine.drug_class ,Anti-Inflammatory Agents, Non-Steroidal ,Prostacyclin ,General Medicine ,Pharmacology ,medicine.disease_cause ,Anti-inflammatory ,chemistry.chemical_compound ,medicine.anatomical_structure ,Mechanism of action ,chemistry ,Prostaglandin-Endoperoxide Synthases ,medicine ,Gastric mucosa ,Animals ,Humans ,Cyclooxygenase Inhibitors ,Antipyretic ,medicine.symptom ,Irritation ,business ,Salicylic acid ,medicine.drug - Abstract
Salicylic acid and salicylates, obtained from natural sources, have long been used as medicaments. Salicylic acid was chemically synthesized in 1860 and was used as an antiseptic, an antipyretic, and an antirheumatic. Almost 40 years later, aspirin was developed as a more palatable form of salicylate. Soon after, other drugs having similar actions to aspirin were discovered, and the group was termed the "aspirin-like drugs" (also now termed the nonsteroidal anti-inflammatory drugs [NSAIDs]). Twenty-five years ago, it was proposed that the mechanism of action of NSAIDs was through their inhibition of prostaglandin biosynthesis. Since then, there has been general acceptance of the concept that these drugs work by inhibition of the enzyme cyclo-oxygenase (COX), which we now know to have at least two distinct isoforms: the constitutive isoform, COX-1, and the inducible isoform, COX-2. COX-1 has clear physiologic functions. Its activation leads, for instance, to the production of prostacyclin, which when released by the endothelium is antithrombogenic and when released by the gastric mucosa is cytoprotective. COX-2, discovered 6 years ago, is induced by inflammatory stimuli and cytokines in migratory and other cells. It is therefore attractive to suggest that the anti-inflammatory actions of NSAIDs are due to inhibition of COX-2, whereas the unwanted side-effects, such as irritation of the stomach lining, are due to inhibition of COX-1. Drugs that have the highest COX-2 activity and a more favorable COX-2: COX-1 activity ratio will have a potent anti-inflammatory activity with fewer side-effects than drugs with a less favorable COX-2: COX-1 activity ratio. The identification of selective inhibitors of COX-2 will therefore lead to advances in therapy.
- Published
- 1998
10. Reduction by prostaglandin E1 or prostaglandin E0 of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels
- Author
-
Emma J. Hide, Christoph Thiemermann, Peter Ney, Julie Piper, and John R. Vane
- Subjects
Male ,medicine.medical_specialty ,Potassium Channels ,ATP-sensitive potassium channel ,Vasodilator Agents ,Myocardial Infarction ,Myocardial Ischemia ,Ischemia ,Blood Pressure ,Myocardial Reperfusion Injury ,Glibenclamide ,Electrocardiography ,chemistry.chemical_compound ,Adenosine Triphosphate ,Heart Rate ,Internal medicine ,Glyburide ,medicine ,Animals ,Hypoglycemic Agents ,Myocardial infarction ,Alprostadil ,Prostaglandin E1 ,Biotransformation ,Pharmacology ,Lagomorpha ,biology ,business.industry ,Myocardium ,medicine.disease ,biology.organism_classification ,Potassium channel ,Endocrinology ,chemistry ,Anesthesia ,Rabbits ,Hydroxy Acids ,business ,Ligation ,Anti-Arrhythmia Agents ,Decanoic Acids ,Research Article ,medicine.drug - Abstract
1. This study examined whether pretreatment of rabbits with infusions of prostaglandin E1 (PGE1) or prostaglandin E0 (PGE0) (which were terminated prior to the onset of ischaemia) reduce myocardial infarct size arising from coronary artery occlusion (60 min) and reperfusion (120 min). In addition, we investigated whether the observed cardioprotective effects of these two prostaglandins were due to the activation of ATP-sensitive potassium (KATP) channels. 2. In the anaesthetized rabbit, infarct size (expressed as a percentage of the area at risk) after 60 min of coronary artery occlusion followed by 2 h of reperfusion was 59 +/- 4% (n = 10). PGE1 or PGE0 treatment (1.0 micrograms kg-1 min-1), administered as 1 h pretreatments (0.05 ml min-1, i.v.), significantly reduced infarct size to 44 +/- 6% (n = 6) or 42 +/- 1% (n = 6), respectively. PGE1 or PGE0 pretreatment resulted in a significant reduction in mean arterial blood pressure, which returned to baseline within 15 min of discontinuation of the infusion (i.e. prior to LAL ligation). 3. The reduction in infarct size afforded by PGE1 was abolished by pretreatment of rabbits with the KATP channel blockers, glibenclamide (60 +/- 4%; n = 8) or 5-hydroxydecanoate (58 +/- 6%; n = 6). Similarly, glibenclamide also largely attenuated the reduction in infarct size afforded by PGE0 (52 +/- 3%; n = 8). 4. We propose that a 1 h pretreatment of PGE1 or PGE0 reduces infarct size by activating protein kinase C resulting in the opening of KATP channels.
- Published
- 1995
11. Roles of endothelin receptors in the regional and systemic vascular responses to ET-1 in the anaesthetized ganglion-blocked rat: use of selective antagonists
- Author
-
Graham H. Allcock, Timothy D. Warner, and John R. Vane
- Subjects
Endothelin Receptor Antagonists ,Male ,medicine.medical_specialty ,Vascular smooth muscle ,Ganglionic Blockers ,Ganglionic blocker ,Blood Pressure ,Vasodilation ,In Vitro Techniques ,Hexamethonium ,Peptides, Cyclic ,chemistry.chemical_compound ,Piperidines ,Internal medicine ,medicine ,Animals ,Anesthesia ,Cardiac Output ,Rats, Wistar ,Receptor ,Pharmacology ,Receptors, Endothelin ,Endothelins ,Hemodynamics ,Endothelin 1 ,Microspheres ,Rats ,Endocrinology ,chemistry ,Regional Blood Flow ,Vascular Resistance ,medicine.symptom ,Endothelin receptor ,Oligopeptides ,Vasoconstriction ,Research Article - Abstract
1. Endothelin-1 (ET-1) produces vasoconstriction, via activation of ETA and ETB receptors on vascular smooth muscle, and vasodilatation via ETB receptors on endothelial cells. Here we have used the ETA receptor-selective antagonist, BQ-123, the ETB receptor-selective antagonist, BQ-788 and the ETA/ETB receptor non-selective antagonist, PD 145065, to study the role of these receptors in mediating the haemodynamic changes induced by an infusion of ET-1 to the anesthetized ganglion-blocked rat. 2. Infusion of ET-1 (10 pmol kg-1 min-1) increased the mean arterial pressure (MAP) by 57.5 +/- 5.1 mmHg over 70 min. This pressor response was reduced by about 50% by coinfusion of BQ-123 (10 mmol kg-1 min-1), but was unaffected by either BQ-788 (10 nmol kg-1 min-1) or PD 145065 (10 nmol kg-1 min-1). 3. After infusion of ET-1 for 70 min the cardiac output had fallen from 102.6 +/- 11.3 to 55.7 +/- 7.6 ml min-1 and the total peripheral resistance had increased from 3.24 +/- 0.6 to 10.0 +/- 0.8 mmHg ml-1 min-1 (per 100g body weight). BQ-123 decreased the magnitudes of these changes whereas BQ-788 potentiated them. PD 145065 was without effect. 4. ET-1 increased the vascular resistances of all the organs studied except the brain and stomach. These changes were attenuated by BQ-123 in the kidneys, skin, adrenal glands and caecum and potentiated by BQ-788 in the kidneys, small intestine, large intestine and mesentery. PD 145065 had little effect on the individual tissues. 5. Thus, BQ-123, a selective ETA receptor antagonist, inhibits the pressor and vascular constrictor effects of ET-1 more actively than PD 145065. As BQ-788 potentiates some of the vasoconstrictor effects of ET-1 and increases the effects of ET-1 on total peripheral resistance, the predominant role of ETB receptors in the rat circulation is to limit the pressor effects of ET-1.
- Published
- 1995
12. Cytokine-mediated induction of cyclo-oxygenase-2 by activation of tyrosine kinase in bovine endothelial cells stimulated by bacterial lipopolysaccharide
- Author
-
Y.S. Bakhle, P. Akarasereenont, Christoph Thiemermann, and John R. Vane
- Subjects
Lipopolysaccharides ,medicine.medical_specialty ,Platelet-derived growth factor ,medicine.medical_treatment ,Blotting, Western ,Radioimmunoassay ,6-Ketoprostaglandin F1 alpha ,chemistry.chemical_compound ,Western blot ,Epidermal growth factor ,Internal medicine ,medicine ,Animals ,Humans ,Enzyme Inhibitors ,Aorta ,Cells, Cultured ,Platelet-Derived Growth Factor ,Pharmacology ,Analysis of Variance ,Arachidonic Acid ,Dose-Response Relationship, Drug ,Epidermal Growth Factor ,biology ,medicine.diagnostic_test ,Tumor Necrosis Factor-alpha ,Growth factor ,Protein-Tyrosine Kinases ,Recombinant Proteins ,Hydroquinones ,Enzyme Activation ,Endocrinology ,Cytokine ,chemistry ,Prostaglandin-Endoperoxide Synthases ,Enzyme Induction ,biology.protein ,Cytokines ,Cattle ,Tumor necrosis factor alpha ,Endothelium, Vascular ,Tyrosine kinase ,Platelet-derived growth factor receptor ,Interleukin-1 ,Research Article - Abstract
1. The induction of cyclo-oxygenase-2 (COX-2) afforded by bacterial lipopolysaccharide (LPS, endotoxin) in bovine aortic endothelial cells (BAEC) is mediated by tyrosine kinase. LPS also causes the generation of several cytokines including interleukin-1 beta (IL-1 beta), tumour necrosis factor-alpha (TNF-alpha), epidermal growth factor (EGF) and platelet-derived growth factor (PDGF). This study investigates whether endogenous IL-1 beta, TNF-alpha, EGF or PDGF contribute to the induction of COX-2 elicited by LPS in BAEC and if their action is due to activation of tyrosine kinase. Furthermore, we have studied the induction of COX-2 by exogenous cytokines. 2. Accumulation of 6-oxo-prostaglandin (PG) F1 alpha in cultures of BAEC was measured by radioimmunoassay at 24 h after addition of either LPS (1 microgram ml-1) alone or LPS together with a polyclonal antibody to one of the various cytokines. In experiments designed to measure 'COX activity', 6-oxo-PGF1 alpha generated by BAEC activated with recombinant human IL-1 beta, TNF-alpha, EGF or PDGF for 12 h was measured after incubation of washed cells with exogenous arachidonic acid (30 microM for 15 min). Western blot analysis determined the expression of COX-2 protein in BAEC. 3. The accumulation of 6-oxo-PGF1 alpha caused by LPS in BAEC was attenuated by co-incubation with one of the polyclonal antibodies, anti-IL-1 beta, anti-TNF-alpha, anti-EGF, anti-PDGF or with the IL-1 receptor antagonist, in a dose-dependent manner. Exogenous IL-1 beta, TNF-alpha or EGF also caused an increase in COX activity, while PDGF was ineffective. The increase in COX activity elicited by IL-1,beta(10 ng ml-1), TNF-alpha (100 ng ml-1) or EGF (1000 ng ml-1) in BAEC was attenuated by erbstatin (0.005 to 5 microg ml-1), as was the expression of COX-2 protein measured by Western blot analysis.4. PDGF (10 ng ml-1) significantly augmented the rise in COX activity and COX-2 protein caused by shorter incubation of BAEC with LPS (1 microg ml-1 for 3 h). Combination of PDGF (10 ng ml-1) with a low concentration of IL-l beta (1 ng ml-1) for 12 h, also increased 'COX activity', but combination of PDGF and TNF-alpha (10 ng ml-1) did not show any increased activity.5. These results suggest that (i) the induction of COX activity and COX-2 protein elicited by LPS in BAEC is mediated by TNF-alpha with lesser contributions from PDGF, EGF or IL-1 beta; (ii) exogenous IL-1 beta,TNF-alpha or EGF alone induce COX-2 activity and protein in BAEC; (iii) PDGF synergizes with IL-1 beta,but not TNF-alpha, to cause expression of COX-2; and (iv) the induction of COX-2 protein and activity caused by these cytokines involves the activation of tyrosine kinase.
- Published
- 1995
13. Lipocortin 1 mediates the inhibition by dexamethasone of the induction by endotoxin of nitric oxide synthase in the rat
- Author
-
Chin-Chen Wu, Clare E. Bryant, Jamie D. Croxtall, Roderick J. Flower, John R. Vane, Christoph Thiemermann, and Mauro Perretti
- Subjects
Male ,medicine.medical_specialty ,Lipopolysaccharide ,Blotting, Western ,Endogeny ,Stimulation ,Antibodies ,Dexamethasone ,Norepinephrine (medication) ,chemistry.chemical_compound ,Internal medicine ,medicine ,Extracellular ,Animals ,Rats, Wistar ,Cells, Cultured ,Annexin A1 ,Multidisciplinary ,biology ,Chemistry ,Macrophages ,Cell Membrane ,Shock, Septic ,Rats ,Endotoxins ,Nitric oxide synthase ,Endocrinology ,Prostaglandin-Endoperoxide Synthases ,biology.protein ,Amino Acid Oxidoreductases ,Cyclooxygenase ,Hypotension ,Nitric Oxide Synthase ,Research Article ,medicine.drug - Abstract
Administration of Escherichia coli lipopolysaccharide (LPS; 10 mg/kg i.v.) to male Wistar rats caused within 240 min (i) a sustained fall (approximately 30 mmHg) in mean arterial blood pressure, (ii) a reduction (> 75%) in the pressor responses to norepinephrine (1 microgram/kg i.v.), and (iii) an induction of nitric oxide synthase (iNOS) as measured in the lung. Dexamethasone (1 mg/kg i.p. at 2 h prior to LPS) attenuated the hypotension and the vascular hyporeactivity to norepinephrine and reduced (by approximately 77%) the expression of iNOS in the lung. These effects of dexamethasone were prevented by pretreatment of LPS-treated rats with a neutralizing antiserum to lipocortin 1 (anti-LC1; 60 mg/kg s.c. at 24 h prior to LPS) but not by a control nonimmune sheep serum. Stimulation of J774.2 macrophages with LPS (1 microgram/ml for 24 h) caused the expression of iNOS and cyclooxygenase 2 (COX-2) protein and significantly increased nitrite generation; this was prevented by dexamethasone (0.1 microM at 1 h prior to LPS), which also increased cell surface lipocortin 1. Pretreatment of J774.2 cells with anti-LC1 (1:60 dilution at 4 h prior to LPS) also abolished the inhibitory effect of dexamethasone on iNOS expression and nitrite accumulation but not that on COX-2 expression. A lipocortin 1 fragment (residues 1-188 of human lipocortin 1; 20 micrograms/ml at 1 h prior to LPS) also blocked iNOS in J774.2 macrophages activated by LPS (approximately 78% inhibition), and this too was prevented by anti-LC1. We conclude that the extracellular release of endogenous lipocortin 1 (i) mediates the inhibition by dexamethasone of the expression of iNOS, but not of COX-2, and (ii) contributes substantially to the beneficial actions of dexamethasone in rats with endotoxic shock.
- Published
- 1995
14. Co-induction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids
- Author
-
John R. Vane, Jane A. Mitchell, Regina M. Botting, Tomasz A. Swierkosz, and Timothy D. Warner
- Subjects
Lipopolysaccharides ,Male ,Nitroprusside ,N-Methylaspartate ,Prostaglandin ,Prostacyclin ,Cycloheximide ,Kidney ,Nitric Oxide ,Nitric oxide ,Mice ,chemistry.chemical_compound ,medicine ,Animals ,Rats, Wistar ,Nitrite ,Lung ,Cells, Cultured ,Pharmacology ,Dose-Response Relationship, Drug ,biology ,Macrophages ,Prostaglandins F ,NADPH Dehydrogenase ,Kidney metabolism ,Molecular biology ,Rats ,Nitric oxide synthase ,chemistry ,Biochemistry ,Prostaglandin-Endoperoxide Synthases ,Enzyme Induction ,Prostaglandins ,biology.protein ,lipids (amino acids, peptides, and proteins) ,Amino Acid Oxidoreductases ,Sodium nitroprusside ,Nitric Oxide Synthase ,Research Article ,medicine.drug - Abstract
1. Lipopolysaccharide (LPS) co-induces nitric oxide synthase (iNOS) and cyclo-oxygenase (COX-2) in J774.2 macrophages. Here we have used LPS-activated J774.2 macrophages to investigate the effects of exogenous or endogenous nitric oxide (NO) on COX-2 in both intact and broken cell preparations. NOS activity was assessed by measuring the accumulation of nitrite using the Griess reaction. COX-2 activity was assessed by measuring the formation of 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha) by radioimmunoassay. Western blot analysis was used to determine the expression of COX-2 protein. We have also investigated whether endogenous NO regulates the activity and/or expression of COX in vivo by measuring NOS and COX activity in the lung and kidney, as well as release of prostanoids from the perfused lung of normal and LPS-treated rats. 2. Incubation of cultured murine macrophages (J774.2 cells) with LPS (1 microgram ml-1) for 24 h caused a time-dependent accumulation of nitrite and 6-keto-PGF1 alpha in the cell culture medium which was first significant after 6 h. The formation of both 6-keto-PGF1 alpha and nitrite elicited by LPS was inhibited by cycloheximide (1 microM) or dexamethasone (1 microM). Western blot analysis showed that J774.2 macrophages contained COX-2 protein after LPS administration, whereas untreated cells contained no COX-2. 3. The accumulation of 6-keto-PGF1 alpha in the medium of LPS-activated J774.2 macrophages was concentration-dependently inhibited by chronic (24 h) exposure to sodium nitroprusside (SNP; 1-1000 microM). Sodium nitroprusside (1-1000 microM) also acutely (30 min) inhibited COX-2 activity in broken cell preparations of LPS-activated (12 h) J774.2 macrophages, in a similar concentration dependent manner. Addition of adrenaline (5 mM) and glutathione (0.1 mM) increased the activity of COX-2 in broken cell preparations. In the presence of these co-factors, SNP inhibited prostanoid production only at the highest concentration used (1 mM). When J774.2 cells were incubated in the presence of LPS (1 microg ml-1) and NG-monomethyl-L-arginine (L-NMMA: 1 mM) for 12 h, SNP at the highest concentration used (1 mM) acutely (30 min) inhibited the activity of COX-2 in cell homogenates with co-factors. However, when J774.2 macrophages were incubated for 24 or 12 h with LPS (1 microg ml-1)and L-NMMA (1 mM), the addition of SNP (0.001-1I000 microM) increased in a concentration-dependent manner the accumulation of 6-keto-PGF1a in intact cells (measured at 24 h) and COX-2 activity in cell homogenates in the presence of co-factors (determined at 12 h). SNP (1 mM; together with LPS for 12 h)decreased the amount of COX-2 protein induced by LPS in J774.2 macrophages.4. Indomethacin (30 1AM) abolished the formation of 6-keto-PGFa by LPS-activated macrophages, but had no effect on the release of nitrite. Conversely, L-NMMA, at the highest concentrations used (1 and 10 mM), increased the release of 6-keto-PGFIa an effect which was reversed by excess L-arginine (3 mM)but not by D-arginine. Similarly, the decrease in nitrite formation caused by L-NMMA was partially reversed by L-arginine (3 mM), but not by D-arginine. L-NMMA (10 mM; together with LPS for 12 h)increased the amount of COX-2 protein induced by LPS in J774.2 macrophages.5. In separate experiments, J774.2 macrophages were activated with LPS (1 microg ml-1), and L-NMMA(10 mM) was added for various times (0.5-24 h) before the collection of mediun at 24 h. L-NMMAenhanced the release of 6-keto-PGFI,, in a time-dependent manner, with the maximal enhancement seen when the NOS inhibitor was incubated with the cells for 24 h. 6. In experiments on male Wistar rats, we investigated the effect of L-NMMA on the release of prostanoids (6-keto-PGF1a prostaglandin E2, thromboxane B2) elicited by arachidonic acid (AA,30nmol) from ex vivo perfused kidneys and lungs. The release from the organs from normal and LPS-treated rats was unaffected by L-NMMA intraperitoneally (30 mg kg-1) for 6 h together with LPS(5 mg kg-1) or LPS vehicle. Similarly, acute (5 min) in vitro exposure to L-NMMA (1 mM) of the perfused organs from control and LPS-treated animals did not change the release of prostanoids elicited by AA (30 nmol).7. These results show that LPS causes the induction of iNOS and COX-2 in J774.2 macrophages. The co-release of NO and PGI2 induced by LPS is dependent on protein synthesis and occurs after a lag-time of 6-12 h. The formation of COX metabolites has no effect on NOS activity whereas NO inhibits both COX-2 activity and induction. These results demonstrate that NOS and COX can be co-induced in vitro and that under these conditions large amounts of NO inhibit the degree of COX expression and activity.In the absence of endogenous NO, lesser amounts of exogenous NO increase the activity of COX-2. In those situations in vivo when the level of NO induction is relatively low, NO does not regulate the increased activity of COX.
- Published
- 1995
15. Glibenclamide-induced inhibition of the expression of inducible nitric oxide synthase in cultured macrophages and in the anaesthetized rat
- Author
-
Christoph Thiemermann, Chin-Chen Wu, and John R. Vane
- Subjects
Lipopolysaccharides ,Male ,Lipopolysaccharide ,In Vitro Techniques ,Pharmacology ,Cell Line ,Glibenclamide ,Mice ,chemistry.chemical_compound ,In vivo ,Glyburide ,Potassium Channel Blockers ,medicine ,Animals ,Rats, Wistar ,Nitrite ,Lung ,Nitrites ,Anesthetics ,biology ,Macrophages ,Hemodynamics ,Tetraethylammonium ,Potassium channel blocker ,Tetraethylammonium Compounds ,Shock, Septic ,Potassium channel ,Rats ,Endotoxins ,Nitric oxide synthase ,Biochemistry ,chemistry ,Enzyme Induction ,biology.protein ,Amino Acid Oxidoreductases ,Nitric Oxide Synthase ,Cromakalim ,Research Article ,medicine.drug - Abstract
1. We have investigated whether glibenclamide, an inhibitor of ATP-sensitive potassium channels, influences the induction of the calcium-independent isoform of nitric oxide synthase (iNOS) in cultured J774.2 macrophages activated by bacterial endotoxin (E.coli lipopolysaccharide; LPS), as well as in the lung and aorta of rats with endotoxic shock. 2. Pretreatment of J774.2 macrophages with glibenclamide (10(-7) to 10(-5) M for 30 min) dose-dependently inhibited the accumulation of nitrite caused by LPS (1 microgram ml-1). In contrast, pretreatment of macrophages with tetraethylammonium (10(-4) to 10(-2) M for 30 min), a non-selective inhibitor of potassium channels, did not affect the rise in nitrite caused by LPS. At the highest concentration (10(-5) M) used, cromakalim, an opener of ATP-sensitive potassium channels, caused a small, but significant inhibition of nitrite formation in macrophages activated with LPS, while lower concentrations (10(-7) to 3 x 10(-6) M) were without effect. 3. The inhibition by glibenclamide (3 microM) of the increase in nitrite induced by LPS in J774.2 macrophages was weaker when glibenclamide was given several hours after LPS, indicating that glibenclamide inhibits the induction, but not the activity, of iNOS. In contrast, the degree of inhibition of nitrite formation caused by the nitric oxide synthase (NOS) inhibitor N omega-nitro-L-arginine methyl ester (L-NAME) was similar when this agent was given up to 10 h after LPS. 4.In anaesthetized rats, LPS caused a fall in mean arterial blood pressure (MAP) from 120 +/-(time 0)to 98 +/- mmHg at 180 min (P
- Published
- 1995
16. New insights into the mode of action of anti-inflammatory drugs
- Author
-
John R. Vane and Regina M. Botting
- Subjects
Lipopolysaccharide ,medicine.drug_class ,medicine.medical_treatment ,Immunology ,Anti-Inflammatory Agents ,Inflammation ,Pharmacology ,Anti-inflammatory ,Steroid ,chemistry.chemical_compound ,medicine ,Animals ,Humans ,Cyclooxygenase Inhibitors ,chemistry.chemical_classification ,biology ,Anti-Inflammatory Agents, Non-Steroidal ,Enzyme ,chemistry ,Drug development ,Biochemistry ,Prostaglandin-Endoperoxide Synthases ,Prostaglandins ,biology.protein ,Steroids ,Arachidonic acid ,Cyclooxygenase ,medicine.symptom - Abstract
The discovery of a second cyclooxygenase has provided fresh impetus to the search for new anti-inflammatory drugs. The second enzyme is effectively absent from healthy tissues but its levels rise dramatically during inflammation. It can be induced in migratory cells by bacterial lipopolysaccharide, cytokines and growth factors. The constitutive cyclooxygenase-1 (COX-1) can thus be considered a "housekeeping" enzyme, in contrast to cyclooxygenase-2 (COX-2) which is activated by tissue damage. Both enzymes have a molecular weight of around 70 kDa and similar Km and Vmax values for their reaction with arachidonic acid. Several non steroid anti-inflammatory drugs which have more than 1,000 fold selectivity for COX-2 over COX-1 are in the early stages of drug development.
- Published
- 1995
17. NG-Hydroxy-L-Arginine Releases from Endothelial Cells Nitric Oxide which Increases cGMP in RFL-6 Fibroblasts
- Author
-
Tomasz A. Swierkosz, John R. Vane, and Timothy D. Warner
- Subjects
medicine.medical_specialty ,Arginine ,biology ,Physiology ,chemistry.chemical_element ,Cell Biology ,General Medicine ,Calcium ,Molecular biology ,Nitric oxide ,Superoxide dismutase ,Nitric oxide synthase ,chemistry.chemical_compound ,Endocrinology ,medicine.anatomical_structure ,chemistry ,Internal medicine ,medicine ,biology.protein ,Bioassay ,Fibroblast ,Dexamethasone ,medicine.drug - Abstract
The release of nitric oxide (NO) by NG-hydroxy-L-arginine (L-OHArg) from endothelial cells (ECs) grown in culture was assessed by two bioassays. The first was a cascade bioassay system, in which the effluent from a column of ECs grown on beads superfused a cascade of isolated endothelium-denuded rabbit aortic strips. Exclusion of calcium from the Krebs' buffer perfusing the ECs (but not from the cascade) diminished the relaxant effects of L-OHArg. Growing the ECs in the presence of dexamethasone did not affect the relaxations of the bioassay cascade induced by L-OHArg. However, these relaxations were potentiated by superoxide dismutase (SOD) and inhibited by haemoglobin, but not inhibited by NG-nitro-L-arginine methyl ester (NO2 ArgMeE). The second bioassay was a transfer assay, in which accumulation of cGMP was measured in detector, RFL-6 fibroblast cells. The accumulation of cGMP induced by the basal release of NO from ECs was increased by L-OHArg and by SOD. However, L-OHArg, unlike SOD, did not scaven...
- Published
- 1995
18. Radioimmunoassay evidence that the pressor effect of big endothelindash1 is due to local conversion to endothelindash1
- Author
-
John R. Vane and Roger Corder
- Subjects
Male ,medicine.hormone ,medicine.medical_specialty ,Vascular smooth muscle ,education ,Radioimmunoassay ,Hemodynamics ,Blood Pressure ,Biochemistry ,Endothelins ,chemistry.chemical_compound ,Internal medicine ,medicine ,Animals ,Protein Precursors ,Rats, Wistar ,Chromatography, High Pressure Liquid ,Pharmacology ,Endothelin-1 ,Chemistry ,Phosphoramidon ,Glycopeptides ,Endothelin 1 ,Rats ,Endocrinology ,Circulatory system ,Arterial blood ,Endothelin receptor - Abstract
Compared with endothelin-1 (ET-1), big endothelin-1 (big ET-1) is only weakly active on isolated vascular smooth muscle preparations. However, on systemic administration high doses of big ET-1 (1 nmol.kg-1) are approximately equipotent to ET-1, indicating the existence of an endothelin converting enzyme in the circulation that rapidly converts big ET-1 to ET-1. In this study arterial blood levels of big ET-1 and ET-1 immunoreactivity were measured after bolus i.v. administration of big ET-1 (1 or 3 nmol.kg-1) or ET-1 (1 nmol.kg-1) in anaesthetised male Wistar rats. In addition, the effect of phosphoramidon (10 mg.kg-1) on the pressor response to big ET-1 and its disappearance rate from the circulation were examined. After big ET-1 injection, circulating ET-1 concentrations did not exceed 2% of the big ET-1 level. Phosphoramidon reduced the pressor response to big ET-1 by 93%, but did not alter its rate of clearance from the circulation. Thus exogenous big ET-1 is converted locally in the vasculature and its disappearance from the circulation is not dependent on conversion to ET-1.
- Published
- 1995
19. Involvement of tyrosine kinase in the induction of cyclo-oxygenase and nitric oxide synthase by endotoxin in cultured cells
- Author
-
Christoph Thiemermann, John R. Vane, P. Akarasereenont, Jane A. Mitchell, and I. Appleton
- Subjects
Lipopolysaccharides ,Cell Survival ,medicine.medical_treatment ,Genistein ,Aorta, Thoracic ,Receptor tyrosine kinase ,Nitric oxide ,Mice ,chemistry.chemical_compound ,medicine ,Animals ,Cells, Cultured ,Pharmacology ,Arachidonic Acid ,biology ,Macrophages ,Protein-Tyrosine Kinases ,Isoflavones ,Molecular biology ,Hydroquinones ,Nitric oxide synthase ,Cytokine ,chemistry ,Prostaglandin-Endoperoxide Synthases ,Enzyme inhibitor ,Enzyme Induction ,biology.protein ,Cattle ,Arachidonic acid ,Amino Acid Oxidoreductases ,Nitric Oxide Synthase ,Tyrosine kinase ,Research Article - Abstract
1. Cyclo-oxygenase (COX) and nitric oxide synthase (NOS) are two enzymes which have distinct cytokine-inducible isoforms (COX-2 and iNOS). Many cytokine receptors have an intracellular tyrosine kinase domain. Here we have used the tyrosine kinase inhibitors, erbstatin and genistein, to investigate the potential role of tyrosine kinase activation in the induction on COX-2 and iNOS caused by endotoxin (lipopolysaccharide; LPS) in bovine aortic endothelial cells (BAEC) and J774.2 macrophages. 2. The main COX metabolites, 6-oxo-prostaglandin F1 alpha (6-oxo-PGF1 alpha) (for BAEC) and PGF2 alpha (for 774.2 macrophages) were measured by radioimmunossay: (i) accumulation of COX metabolites from endogenous arachidonic acid was measured at 24 h after addition of LPS (1 microgram ml-1); (ii) in experiments designed to measure 'COX activity', COX metabolites generated by BAEC or J774.2 macrophages activated with LPS were assayed (at 12 h after LPS administration) after incubation of the washed cells with exogenous arachidonic acid (30 microM for 15 min). Western blot analysis with a specific antibody to COX-2 was used to determine the expression of COX-2 protein caused by LPS in cell extracts. Accumulation of nitrite (measured by the Griess reaction) was used as an indicator of NO formation and, hence, iNOS activity. 3. Erbstatin (0.05 to 5 micrograms ml-1) or genistein (0.5 to 50 micrograms ml-1) caused a dose-dependent inhibition of the accumulation of COX metabolites in the supernatant of BAEC or J774.2 macrophages activated with LPS. Erbstatin or genistein also caused a dose-dependent inhibition of 'COX activity' in both cell types. Western blot analysis showed that erbstatin (5 ig ml1') or genistein (50gg ml-') inhibited the expression of COX-2 protein in BAEC and J774.2 macrophages activated with LPS (lLgml-' for 24 h).4. Erbstatin or genistein also caused a dose-dependent inhibition of nitrite accumulation in J774.2 macrophages activated with LPS (1 sg ml-' for 24 h). In contrast to J774.2 macrophages, BAECstimulated with LPS (1 pg ml-' for 24 h) did not produce detectable amounts (1PiM) of nitrite.5. These results suggest that tyrosine phosphorylation is part of the signal transduction mechanism that mediates (i) the induction of COX-2 and iNOS elicited by LPS in J774.2 macrophages, and (ii) the induction of COX-2 by LPS in BAEC.
- Published
- 1994
20. Modification of metabolism of transplantable and spontaneous murine tumors by the nitric oxide synthase inhibitor, nitro-L-arginine
- Author
-
J. M. Sansom, Gerald E. Adams, Csaba Szabó, Pauline J. Wood, Christoph Thiemermann, Ian J. Stratford, and John R. Vane
- Subjects
Cancer Research ,medicine.medical_specialty ,Arginine ,Mammary Neoplasms, Animal ,Nitroarginine ,Mice ,chemistry.chemical_compound ,In vivo ,Internal medicine ,Animals ,Medicine ,Radiology, Nuclear Medicine and imaging ,Amino acid oxidoreductases ,Mice, Inbred C3H ,Radiation ,Tumor hypoxia ,biology ,business.industry ,Metabolism ,Molecular biology ,Nitric oxide synthase ,Endocrinology ,Oncology ,chemistry ,Anesthetic ,Carcinoma, Squamous Cell ,biology.protein ,Amino Acid Oxidoreductases ,Nitric Oxide Synthase ,business ,Neoplasm Transplantation ,medicine.drug - Abstract
Purpose: To determine the effects of the nitric oxide synthase inhibitor, nitro-L-arginine on energy metabolism in transplantable and spontaneous murine tumors. Methods and Materials: The responses of the transplantable murine tumor SCCVII/Ha and a range of spontaneously arising murine mammary adenocarcinomas to 10 mg/kg IV nitro-L-arginine were examined using in vivo 31 P magnetic resonance spectroscopy (MRS). The influence of Hypnorm/Hypnovel anesthesia on the response to nitro-L-arginine was also determined in the SCCVII/Ha tumors. Data were expressed as changes in the inorganic phosphate peak area relative to the sum of all peak areas from the 31 P MR spectrum, or Pi/total. Results: Nitro-L-arginine at 10 mg/kg IV increased Pi/total 2–3-fold in the SCCVII/Ha tumors for at least 2 h after administration, in both anesthetized and nonanesthetized mice, consistent with increased tumor hypoxia. Similar increases in Pi/total were observed after 10 mg/kg IV nitro-L-arginine in 13 spontaneous murine tumors from three different mouse strains, where anesthetic was used. Conclusion: The results indicate that tumor metabolism may be modified by an inhibitor of nitric oxide synthesis, that this modification occurs in both transplantable and spontaneous murine tumors and is not affected by anesthetic.
- Published
- 1994
21. Characterization of ETB receptors mediating contractions induced by endothelin-1 or IRL 1620 in guinea-pig isolated airways: effects of BQ-123, FR139317 or PD 145065
- Author
-
Timothy D. Warner, Bruno Battistini, Alain Fournier, and John R. Vane
- Subjects
Endothelin Receptor Antagonists ,Male ,medicine.hormone ,Agonist ,medicine.medical_specialty ,Indoles ,Contraction (grammar) ,medicine.drug_class ,Guinea Pigs ,Respiratory System ,In Vitro Techniques ,Peptides, Cyclic ,Endothelins ,chemistry.chemical_compound ,Internal medicine ,medicine ,Animals ,Receptor ,Pharmacology ,BQ-123 ,Dose-Response Relationship, Drug ,Receptors, Endothelin ,Azepines ,respiratory system ,Endothelin 1 ,Peptide Fragments ,Endocrinology ,chemistry ,Mechanism of action ,Respiratory Physiological Phenomena ,medicine.symptom ,Endothelin receptor ,Oligopeptides ,Muscle Contraction ,Research Article - Abstract
1. We have characterized the receptors mediating contractions to endothelin-1 (ET-1) or IRL 1620, an ETB receptor selective agonist, in isolated strips of tissue prepared from different parts of the guinea-pig airways. We used as antagonists BQ-123 and FR139317 (ETA receptor-selective) and PD 145065 (ETA/ETB receptor non-selective). 2. ET-1 and IRL 1620 (10(-10) M to 10(-6) M) caused similar concentration-dependent contractions of strips of guinea-pig trachea and upper bronchus. In the guinea-pig trachea without epithelium or lung parenchyma, IRL 1620 was less potent than ET-1. 3. In the trachea, contraction to ET-1 (< 10(-8) M) was preceded by a transient relaxation which was inhibited by BQ-123 (10(-5) M) or FR 139317 (10(-5) M) or by the removal of the epithelium. The concentration-response curve to ET-1 in the trachea was shifted to the right by PD 145065 (10(-5) M to 10(-4) M). PD 145065 (10(-4) M) also inhibited the response to ET-1 (3 x 10(-7) M) by 55%. Contractions induced by IRL 1620 were not affected by BQ-123 (10(-6) M) or FR139317 (10(-6) M) but were significantly attenuated by 10(-5) M of either antagonist. PD 145065 at 10(-6) M strongly attenuated and at 10(-5) M abolished contractions induced by IRL 1620. 4. In the trachea, removal of the epithelium potentiated the effects of both agonists. BQ-123 (10-5 M)had no effect on contractions of the trachea without epithelium induced by ET-1, but FR139317 (10-5 M)caused a significant inhibition. PD 145065 (10-5 M to 10-4 M) caused a shift to the right of the ET-1 concentration-response curve without affecting the contractile effect at 3 x 10-7 M. All three antagonists inhibited contractions induced by IRL 1620.5. In the upper bronchus, BQ-123 (10-5 M) did not affect contractions induced by ET-1, whileFR139317 (10-5 M) attenuated (20-26%) only contractions induced by 1-3 x 10-7 M ET-1. PD 145065(10-5 M to 10-4 M) caused a shift to the right of the ET-1 concentration-response curve. The contractions induced by IRL 1620 were inhibited by BQ-123 or FR139317 (10-5M to 10-4 M). PD 145065(10-6 M) strongly inhibited contractions induced by IRL 1620 and PD 145065 (10-5 M) totally abolished them.6. The contractile action of ET-1 in the lung parenchyma was significantly and similarly attenuated by BQ-123 (10-5 M) or indomethacin (10-5 M), while FRI39317 (10-5 M) was less effective. PD 145065(10-6 to 10-5 M) inhibited contractions to ET-1. IRL 1620, which is less potent than ET-1 in this preparation, was antagonized by PD 145065 (10-5 to 10-6 M) but unaffected by BQ-123 (10-6 M to10-5M) or FR139317 (10-6 M).7. Thus, ETB receptors mediate contractions to ET-1 in all four guinea-pig airway preparations. In addition, contractions to ET-1 in the trachea and lung parenchyma are mediated in part by ETA receptors. In the latter tissue, these ETA receptors mediate contraction through the release of cyclooxygenase metabolites. Similarly, ETA receptors located on the epithelial cells also mediate the release of prostanoids in the trachea with epithelium but they are responsible for transient relaxations. Interestingly,contractions induced by IRL 1620 were more susceptible to inhibition by the different antagonists,most probably because it binds to the endothelin receptors in a reversible manner. High concentrations(10-5 M) of ETA-selective antagonists also inhibit responses to IRL 1620, most probably by an effect at ETB receptors in both the trachea and the upper bronchus.
- Published
- 1994
22. Evidence from receptor antagonists of an important role for ETB receptor-mediated vasoconstrictor effects of endothelin-1 in the rat kidney
- Author
-
Timothy D. Warner, Robert P. Wellings, John R. Vane, Roger Corder, Jean-Paul Cristol, and Christoph Thiemermann
- Subjects
Endothelin Receptor Antagonists ,Male ,medicine.hormone ,medicine.medical_specialty ,Mean arterial pressure ,Indoles ,medicine.drug_class ,Indomethacin ,Molecular Sequence Data ,Blood Pressure ,Viper Venoms ,In Vitro Techniques ,Peptides, Cyclic ,Renal Circulation ,Endothelins ,Internal medicine ,medicine ,Animals ,Vasoconstrictor Agents ,Anesthesia ,Amino Acid Sequence ,Rats, Wistar ,Pharmacology ,Renal circulation ,Chemistry ,Azepines ,Receptor antagonist ,Endothelin 1 ,Rats ,Endocrinology ,medicine.anatomical_structure ,Vasoconstriction ,cardiovascular system ,Vascular Resistance ,medicine.symptom ,Endothelin receptor ,Oligopeptides ,Research Article ,circulatory and respiratory physiology - Abstract
1. To characterize the receptor subtype(s) mediating the renal vasoconstrictor effects of the endothelin (ET) and sarafotoxin (SX) peptides in the isolated perfused kidney of the rat, we have examined the effects of endothelin-1 (ET-1), sarafotoxin 6b (SX6b) and sarafotoxin 6c (SX6c) as agonists, BQ-123 and FR 139317 as selective ETA receptor antagonists, and PD 145065 as a non-selective (ETA and ETB) receptor antagonist. We have also compared in the anaesthetized rat the systemic pressor and renal vasoconstrictor effects of ET-1 and SX6c alone or after pretreatment with PD 145065. 2. In the isolated perfused kidney, ET-1, SX6b and SX6c all gave similar concentration-dependent increases in perfusion pressure. The ETA receptor selective antagonists, BQ-123 and FR 139317, both partially blocked the increase in perfusion pressure induced by ET-1. In contrast, PD 145065 completely blocked the increase in perfusion pressure caused by ET-1. 3. Indomethacin (10 microM) had no effect on the ET-1-induced increases in perfusion pressure but significantly reduced the vasoconstriction induced by low concentrations of SX6c, without affecting responses to high concentrations. In the anaesthetized rat, indomethacin (5 mg kg-1) did not modify the systemic pressor or renal vasoconstrictor effects of ET-1 or SX6c. 4. In anaesthetized rats, bolus intravenous injections of ET-1 or SX6c (0.1, 0.25, 0.5 or 1.0 nmol kg-1) produced initial transient depressor responses followed by sustained and dose-dependent increases in mean arterial pressure (MAP). Both peptides caused an equipotent fall in renal blood flow (RBF).PD 145065 (5 mg kg-1) partially antagonized the systemic pressor effects of ET-1 and SX6c but completely blocked the fall in RBF and rise in renal vascular resistance (RVR) induced by ET-1 and SX6c. PD 145065 also antagonized the transient depressor effect following the bolus administration of either ET-1 or SX6c.5. These results indicate that ET/SX induced renal vasoconstriction is mediated via ETA and ETB-like receptors with ETB receptors having a predominant role in vivo. This may be of therapeutic relevance for an ETA receptor-selective antagonist may offer only limited protection against the deleterious renal effects of endogenous ETs.
- Published
- 1994
23. The Croonian Lecture, 1993. The endothelium: maestro of the blood circulation
- Author
-
John R. Vane
- Subjects
medicine.medical_specialty ,Endothelium ,Arteriosclerosis ,Blood Pressure ,Vasodilation ,Prostacyclin ,Nitric Oxide ,Muscle, Smooth, Vascular ,General Biochemistry, Genetics and Molecular Biology ,Internal medicine ,Renin–angiotensin system ,medicine ,Animals ,Humans ,Myocardial infarction ,biology ,business.industry ,Endothelins ,Angiotensin-converting enzyme ,medicine.disease ,Epoprostenol ,Angiotensin II ,medicine.anatomical_structure ,Endocrinology ,Vasoconstriction ,Pathophysiology of hypertension ,Blood Circulation ,cardiovascular system ,biology.protein ,Endothelium, Vascular ,General Agricultural and Biological Sciences ,business ,medicine.drug - Abstract
The vascular endothelium plays a vital role in the control of the circulation. It metabolizes various vasoactive substances, coverts angiotensin I to angiotensin II and secretes the potent vasodilators prostacyclin and EDRF(NO) and the vasoconstrictor peptide endothelin-1. The balance between these mediators determines the responses of the cardiovascular system in diseases such as hypertension, atherosclerosis and myocardial infarction.
- Published
- 1994
24. Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide
- Author
-
John R. Vane, Jane A. Mitchell, Csaba Szabó, Chin-Chen Wu, Steven S. Gross, and Christoph Thiemermann
- Subjects
Lipopolysaccharides ,Male ,medicine.medical_specialty ,Lipopolysaccharide ,Physiology ,medicine.drug_class ,Cardiovascular System ,Nitric oxide ,Mice ,chemistry.chemical_compound ,In vivo ,Internal medicine ,medicine ,Animals ,Platelet Activating Factor ,Rats, Wistar ,Cells, Cultured ,Nitrites ,Platelet-activating factor ,biology ,Macrophages ,Azepines ,Triazoles ,Receptor antagonist ,Rats ,Vasomotor System ,Nitric oxide synthase ,Endocrinology ,chemistry ,Enzyme Induction ,biology.protein ,Blood Vessels ,Tumor necrosis factor alpha ,Amino Acid Oxidoreductases ,Nitric Oxide Synthase ,Cardiology and Cardiovascular Medicine ,Ex vivo - Abstract
This study investigates the role of endogenous platelet-activating factor (PAF) in the production of nitric oxide (NO) by constitutive and inducible isoforms of NO synthase (NOS) in endotoxin shock. In anesthetized rats, 3 hours of endotoxemia resulted in a fall in mean arterial blood pressure (MAP) from 127 +/- 5 (control) to 61 +/- 7 mm Hg and a reduction of the pressor responses to norepinephrine (NE, 1 microgram.kg-1) from 33 +/- 3 (control) to 17 +/- 2 mm Hg. Endotoxemia for 3 hours also resulted in a significant reduction in the contractile effects of NE (10(-8) to 10(-6) mol/L) in thoracic aortas ex vivo. This hyporeactivity to NE was due to an enhanced formation of NO, for it was restored by the NOS inhibitor NG-nitro-L-arginine methyl ester. Animals pretreated with the PAF receptor antagonist WEB 2086 maintained higher MAP (MAP at 180 minutes, 98 +/- 6 mm Hg) and exhibited more pronounced pressor responses to NE at 180 minutes after LPS injection. Moreover, WEB 2086 attenuated by 58% the lipopolysaccharide (LPS)-induced hyporeactivity of the rat aortic rings ex vivo. At 3 hours after LPS injection, calcium-independent NOS activity was induced in the lung. The activity of inducible NOS was significantly lower (by 31%) in lungs of rats pretreated with WEB 2086. The hypothesis that WEB 2086 attenuates the induction of NOS in vivo was substantiated in vitro by the finding that pretreatment with WEB 2086 for 30 minutes inhibited the LPS-stimulated NO production in cultured murine macrophages.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1993
25. Interleukin-1 contributes to the induction of nitric oxide synthase by endotoxin in vivo
- Author
-
John R. Vane, Steven S. Gross, Christoph Thiemermann, Chin-Chen Wu, and Csaba Szabó
- Subjects
Male ,medicine.drug_class ,Sialoglycoproteins ,Aorta, Thoracic ,Blood Pressure ,Vasodilation ,Biology ,Pharmacology ,Muscle, Smooth, Vascular ,Nitric oxide ,Norepinephrine ,chemistry.chemical_compound ,Heart Rate ,In vivo ,medicine.artery ,Escherichia coli ,medicine ,Animals ,Thoracic aorta ,Rats, Wistar ,Lung ,Interleukin ,Receptor antagonist ,Recombinant Proteins ,Rats ,Endotoxins ,Nitric oxide synthase ,Interleukin 1 Receptor Antagonist Protein ,chemistry ,Enzyme Induction ,Immunology ,biology.protein ,Amino Acid Oxidoreductases ,Nitric Oxide Synthase ,Ex vivo ,Interleukin-1 ,Muscle Contraction - Abstract
We investigated the role of interleukin-1 in the induction of a Ca 2+ -independent nitric oxide (NO) synthase by bacterial endotoxin in vivo. In anaesthetized rats, pretreatment with interleukin-1 receptor antagonist (interleukin-1 ra ; 16 mg kg −1 i.v., followed by an infusion of 2.4 mg kg −1 h −1 ) ameliorated the delayed hypotension and tachycardia in response to endotoxin (2 mg kg −1 i.v.). Endotoxaemia for 3 h induced a Ca 2+ -inependent NO synthase activity in the lung and reduced the contractions to noradrenaline in the thoracic aorta ex vivo. Treatment with interleukin-1 ra attenuated both the induction of NO synthase in the lung (by 46±5%) and the endotoxin-induced hyporeactivity to noradrenaline in the aorta. Thus, endogenous interleukin-1 contributes to the induction of NO synthase in response to endotoxin in vivo.
- Published
- 1993
26. Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF
- Author
-
Roger Corder, Timothy D. Warner, John R. Vane, and Graham H. Allcock
- Subjects
Endothelin Receptor Antagonists ,Male ,medicine.hormone ,medicine.medical_specialty ,medicine.drug_class ,Molecular Sequence Data ,Aorta, Thoracic ,Viper Venoms ,In Vitro Techniques ,Pulmonary Artery ,Biology ,Nitric Oxide ,Peptides, Cyclic ,Muscle, Smooth, Vascular ,Endothelins ,chemistry.chemical_compound ,Internal medicine ,medicine ,Animals ,Vasoconstrictor Agents ,Amino Acid Sequence ,Rats, Wistar ,Receptor ,Pharmacology ,BQ-123 ,Receptors, Endothelin ,Stomach ,Muscle, Smooth ,Smooth muscle contraction ,BQ-788 ,Receptor antagonist ,Endothelin 1 ,Rats ,Vasodilation ,Endocrinology ,chemistry ,cardiovascular system ,Rabbits ,Endothelin receptor ,Oligopeptides ,Research Article ,Muscle Contraction ,circulatory and respiratory physiology - Abstract
1. We have compared the receptors mediating the contractions of rings of rat thoracic aorta or rabbit pulmonary artery and rat stomach strips in response to the endothelin/sarafotoxin (ET/SX) family of peptides and to those mediating endothelium-dependent vasodilations within the isolated perfused mesentery of the rat. To discriminate ETA receptors from ETB receptors we have used the criteria that ET-1 is more active than SX6c on ETA receptors, and that the ET/SX peptides are equiactive on ETB receptors. We have also assessed the effects of the ETA receptor-selective antagonist BQ-123, and the non-selective ET receptor antagonist PD 142893 on the responses of each preparation to the ET/SX peptides. 2. ET-1-induced constrictions of the rat thoracic aorta (EC50 3 x 10(-10) M), a prototypic ETA receptor-mediated response, or isolated perfused mesentery of the rat were antagonized by BQ-123 (10(-5) M) or PD 142893 (10(-5) M). SX6c did not constrict either the rat isolated perfused mesentery or the rat thoracic aorta. Thus, ETA receptors mediate these constrictions. 3. ET-1 and SX6c were approximately equipotent in constricting rabbit pulmonary artery rings (EC50S 3-6 x 10(-10) M). Neither BQ-123 (10(-5) M) nor PD 142893 antagonized the contractions induced by ET-1. These effects suggest mediation by ETB receptors but PD 142893 (10(-5) M) did give a 3 fold antagonism of constrictions induced by SX6c. 4. SX6c was more potent than ET-1 in contracting the rat stomach strip (threshold concentrations 10(-10) and 3 x 10(-10) M). Contractions to ET-1 or SX6c were unaffected by BQ-123 (10-5 M), again indicative of ETB receptor-mediated events. PD 142893 (10-5 M) was ineffective against ET-1 but produced a 3 fold antagonism of SX6c.5. In the rat isolated perfused mesentery ET-1 or SX6c (0.3-300pmol) were equipotent in producing dose-related vasodilatations that were unaffected by BQ-123 (10-6 M), indicative of an ETB receptor mediated response. In contrast to the other ETB-mediated responses, PD 142893 (10-6 M) strongly antagonized these vasodilatations.6. Thus, ETA receptors mediate constrictions of the rat thoracic aorta and rat isolated perfused mesentery whereas ETB receptors mediate constrictions of the rabbit pulmonary artery and rat stomach strip and endothelium-dependent dilatations within the mesentery. However, within the group of ETB receptor-mediated responses, endothelium-dependent vasodilatations are sensitive to PD 142893, whereas contractions of the isolated smooth muscle preparations are not. Thus, the receptor present on the endothelium responsible for the release of nitric oxide in response to the ET/SX peptides is most probably different from that present on smooth muscle that mediates BQ-123-insensitive contractions.
- Published
- 1993
27. Characterization of endothelin receptors mediating the effects of the endothelin/sarafotoxin peptides on autonomic neurotransmission in the rat vas deferens and guinea-pig ileum
- Author
-
John R. Vane, Graham H. Allcock, Emma J. Mickley, and Timothy D. Warner
- Subjects
Endothelin Receptor Antagonists ,Male ,medicine.hormone ,medicine.medical_specialty ,Guinea Pigs ,Molecular Sequence Data ,Stimulation ,Viper Venoms ,In Vitro Techniques ,Biology ,Neurotransmission ,Autonomic Nervous System ,Peptides, Cyclic ,Synaptic Transmission ,Endothelins ,Vas Deferens ,Ileum ,Internal medicine ,medicine ,Animals ,Vasoconstrictor Agents ,Amino Acid Sequence ,Rats, Wistar ,Receptor ,Pharmacology ,Receptors, Endothelin ,Vas deferens ,Endothelin 1 ,Electric Stimulation ,Rats ,medicine.anatomical_structure ,Endocrinology ,cardiovascular system ,medicine.symptom ,Endothelin receptor ,Oligopeptides ,Research Article ,Muscle Contraction ,Muscle contraction - Abstract
1. To characterize the receptors mediating the effects of the endothelin/sarafotoxin family of peptides on the responses to electrical stimulation of the rat vas deferens (RVD) and guinea-pig ileum (GPI) we have used endothelin-1 (ET-1), ET-3, sarafotoxin 6b (SX6b) and SX6c as agonists and the endothelin-receptor antagonists BQ-123 (ETA receptor selective) and PD 142893 (non-selective). 2. In the RVD, ET-1 and SX6b increased the twitches induced by field stimulation starting at a threshold concentration of 10(-10) M while the threshold concentration for ET-3 was 3 x 10(-9) M. SX6c (up to 3 x 10(-8) M) did not potentiate the twitches. SX6b produced significantly (P0.05) greater potentiations than ET-1 at concentrations of 3 x 10(-9) M and higher, and 10(-7) M ET-3 also produced a significantly greater effect than ET-1 at the same concentration. Thus, at threshold the rank order of peptides was ET-1 = SX6bET-3SX6c, and at concentrations of 3 x 10(-8) M and higher, SX6bET-3ET-1SX6c. 3. In the presence of BQ-123 or PD 142893 (10(-5) M) the threshold concentrations for ET-1 to augment the twitches were increased 30 fold. In the same conditions neither SX6b nor ET-3 potentiated the responses. The relative activities of the endothelin/sarafotoxin peptides and the effectiveness of the endothelin receptor antagonists are consistent with postjunctional ETA receptors mediating these effects. 4. In the transmurally stimulated GPI the endothelin/sarafotoxin peptides produced two effects; an increase in the basal tension of the tissues and an inhibition of the twitch responses. To increase the basal tension the peptides had the order of potency ET-1SX6bET-3 = SX6c. These direct effects of ET-1 or SX6b were strongly antagonized (100 fold) by either BQ-123 (10-5M) or PD 142893(10-5 M). Thus, ETA receptors mediate contractions of the GPI induced by these peptides.5. The endothelin/sarafotoxin peptides were approximately equipotent at depressing twitches of the GPI in response to transmural stimulation (EC50s, 4 x 10-11 to 1.5 x 10-10 M). The depressions induced byET-1 were unaffected by either BQ-123 (10-5 M) or PD 142893 (10-5 M). BQ-123 produced a small(three fold) antagonism of the inhibitory effects of ET-3 or SX6c. These results indicate that a receptor of the ETB type mediates the inhibitory effects of the endothelin/sarafotoxin peptides on neurotransmission in the GPI.6. Thus, both ETA receptors and ETB receptors mediate the effects of the endothelin/sarafotoxinpeptides on neurotransmission.
- Published
- 1993
28. Mediation of endothelin-1-induced inhibition of platelet aggregation via the ETB receptor
- Author
-
Christoph Thiemermann, Lorraine McMurdo, Paul S. Lidbury, and John R. Vane
- Subjects
Endothelin Receptor Antagonists ,Male ,medicine.medical_specialty ,Mean arterial pressure ,Indoles ,Platelet Aggregation ,Blood Pressure ,Prostacyclin ,Bolus (medicine) ,Internal medicine ,medicine ,Animals ,Pharmacology ,Receptors, Endothelin ,Chemistry ,Endothelins ,Hemodynamics ,Antagonist ,Azepines ,Endothelin 1 ,Blood pressure ,Endocrinology ,Vasoconstriction ,Rabbits ,Endothelin receptor ,Oligopeptides ,Platelet Aggregation Inhibitors ,Ex vivo ,Research Article ,medicine.drug - Abstract
1. The effects of FR139317 (ETA antagonist) or PD145065 (non-selective ETA/ETB antagonist) on endothelin-1 (ET-1)-induced changes in blood pressure and inhibition of ex vivo platelet aggregation were investigated in the anaesthetized rabbit. 2. ET-1 (1 nmol kg-1, i.a. bolus) caused a sustained increase in mean arterial pressure (MAP) (peak increase 47 +/- 5 mmHg, n = 8). Intravenous infusion of FR139317 at 0.2 (n = 4) or 0.6 mg kg-1 min-1 (n = 4) inhibited the ET-1 pressor response by 83 or 89%, respectively. Infusion of PD145065 at 0.2 (n = 4) or 0.6 mg kg-1 min-1 (n = 4) inhibited the ET-1-induced increase in MAP by 79 or 75%, respectively. 3. The transient depressor response (-16 +/- 3 mmHg) which preceded the rise in blood pressure induced by ET-1 (1 nmol kg-1, i.a., n = 8) was enhanced by an intravenous infusion of FR139317 (0.6 mg kg-1 min-1) to -35 +/- 5 mmHg (P0.05, n = 4). This enhancement was abolished by indomethacin (5 mg kg-1, i.v.) pretreatment (-17 +/- 1 mmHg, n = 4). PD145065 (0.2 mg kg-1 min-1, i.v.) attenuated the ET-1-induced fall in blood pressure to -9 +/- 1 mmHg (n = 4), while a higher dose of this antagonist (0.6 mg kg-1 min-1, i.v.) completely abolished the ET-1-mediated depressor response. 4. ET-1 (1 nmol kg-1, n = 8) inhibited ex vivo platelet aggregation by 96% at 5 min after injection of the peptide. FR139317 (0.2 or 0.6 mg kg-1 min-1, i.v.) or PD145065 (0.2mg kg-1 min-1, i.v.) did not affect the inhibition of ex vivo platelet aggregation in response to ET-1. In contrast, intravenous infusion of PD145065 (0.6 mg kg-1 min-1) abolished the anti-aggregatory effects of ET-1.5. Thus, FR139317 inhibits the pressor, but not the depressor actions of ET-1 and has no effect on the ET-l-induced inhibition of ex vivo platelet aggregation. In contrast, PD145065 antagonizes the pressor and depressor responses to ET-1 and abolishes the anti-aggregatory effects of the peptide.6. These results strongly suggest that ET-1-induced vasoconstriction in the anaesthetized rabbit is primarily mediated via the ETA receptor while the depressor and antiaggregatory actions of ET-1 are due to activation of the ETB receptor.
- Published
- 1993
29. Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock
- Author
-
Jane A. Mitchell, John R. Vane, Csaba Szabó, and Christoph Thiemermann
- Subjects
Lipopolysaccharides ,Male ,medicine.medical_specialty ,Lipopolysaccharide ,Blood Pressure ,Nitric Oxide ,Dexamethasone ,Nitric oxide ,Norepinephrine ,chemistry.chemical_compound ,Heart Rate ,Internal medicine ,Escherichia coli ,medicine ,Animals ,Anesthesia ,Rats, Wistar ,Enzyme inducer ,Pharmacology ,biology ,Hemodynamics ,Shock, Septic ,Rats ,Nitric oxide synthase ,Endocrinology ,medicine.anatomical_structure ,chemistry ,Enzyme Induction ,Circulatory system ,Catecholamine ,biology.protein ,Amino Acid Oxidoreductases ,Nitric Oxide Synthase ,Research Article ,Blood vessel ,medicine.drug - Abstract
1. The role of an enhanced formation of nitric oxide (NO) and the relative importance of the constitutive and inducible NO synthase (NOS) for the development of immediate (within 60 min) and delayed (at 180 min) vascular hyporeactivity to noradrenaline was investigated in a model of circulatory shock induced by endotoxin (lipopolysaccharide; LPS) in the rat. 2. Male Wistar rats were anaesthetized and instrumented for the measurement of mean arterial blood pressure (MAP) and heart rate. In addition, the calcium-dependent and calcium-independent NOS activity was measured ex vivo by the conversion of [3H]-arginine to [3H]-citrulline in homogenates from several organs obtained from vehicle- and LPS-treated rats. 3. E. coli LPS (10 mg kg-1, i.v. bolus) caused a rapid (within 5 min) and sustained fall in MAP. At 30 and 60 min after LPS, pressor responses to noradrenaline (0.3, 1 or 3 micrograms kg-1, i.v.) were significantly reduced. The pressor responses were restored by NG-nitro-L-arginine methyl ester (L-NAME, 1 mg kg-1, i.v. at 60 min), a potent inhibitor of NO synthesis. In contrast, L-NAME did not potentiate the noradrenaline-induced pressor responses in control animals. 4. Dexamethasone (3 mg kg-1, i.v., 60 min prior to LPS), a potent inhibitor of the induction of NOS, did not alter initial MAP or pressor responses to noradrenaline in control rats, but significantly attenuated the LPS-induced fall in MAP at 15 to 60 min after LPS. Dexamethasone did not influence the development of the LPS-induced immediate (within 60 min) hyporeactivity to noradrenaline. However,dexamethasone pretreatment prevented the hypotension and vascular hyporeactivity at 180 min.5. At 60 min after LPS a moderate increase in the activity of a calcium-independent (inducible) NOS activity was detected in the aorta, but not in any of the other tissues studied. However, at 180 min after LPS, a significant NOS induction was observed in the lung, liver, spleen, mesentery, heart and aorta.This NOS induction was substantially prevented by pretreatment with dexamethasone.6. These results suggest that the immediate hypotension and vascular hyporeactivity to noradrenaline in endotoxin shock is caused by an enhanced formation of NO due to activation of the constitutive enzyme. The delayed hypotension and vascular hyporeactivity, however, is due to enhanced NO formation by the LPS-induced enzyme.
- Published
- 1993
30. Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat
- Author
-
Jean-Paul Cristol, John R. Vane, Timothy D. Warner, and Christoph Thiemermann
- Subjects
Endothelin Receptor Antagonists ,Male ,medicine.hormone ,medicine.medical_specialty ,Viper Venoms ,Peptides, Cyclic ,Renal Circulation ,Endothelins ,chemistry.chemical_compound ,Internal medicine ,medicine ,Animals ,Vasoconstrictor Agents ,Anesthesia ,Rats, Wistar ,Pharmacology ,BQ-123 ,Kidney ,Renal circulation ,Receptors, Endothelin ,business.industry ,Hemodynamics ,Rats ,Endocrinology ,medicine.anatomical_structure ,chemistry ,Vasoconstriction ,Renal blood flow ,cardiovascular system ,medicine.symptom ,business ,Endothelin receptor ,Research Article ,circulatory and respiratory physiology - Abstract
1. Using endothelin-1 (ET-1), endothelin-3 (ET-3), sarafotoxin 6b (SX6b) and sarafotoxin 6c (SX6c) as agonists and BQ-123 as a selective ETA receptor antagonist, we have examined the endothelin receptor subtypes mediating the systemic pressor and renal vasoconstrictor effects of the ET/SX family of peptides. 2. In anaesthetized rats, bolus intravenous injections of ET-1, ET-3, SX6b or SX6c (0.1, 0.25 and 0.50 nmol kg-1) produced initial transient depressor responses followed by sustained and dose-dependent increases in mean arterial pressure (MAP) with the following rank order of potency: SX6b > ET-1 >> SX6c > ET-3. In contrast, in the renal vasculature these peptides caused equipotent dose-dependent falls in renal blood flow (RBF) (ET-1 = ET-3 = SX6b = SX6c). 3. BQ-123 (1 mg kg-1, i.v. bolus) significantly reduced the systemic pressor effects of all the peptides but was largely ineffective against the renal vasoconstrictions. 4. These results indicate that although the systemic pressor effects of the ET/SX peptides are mediated via ETA receptors, the vasoconstriction in the kidney in vivo may be mediated predominantly via ETB-like receptors. This may be of therapeutic relevance, for an ETA-receptor-selective antagonist could offer only poor protection of the renal circulation from the deleterious effects of endogenously produced members of this peptide family.
- Published
- 1993
31. Effects of Phosphoramidon in Endothelial Cell Cultures on the Endogenous Synthesis of Endothelin-1 and on Conversion of Exogenous Big Endothelin-1 to Endothelin-1
- Author
-
Noorafza Q. Khan, Erik Änggård, Vanessa J. Harrison, Roger Corder, and John R. Vane
- Subjects
Cell type ,Molecular Sequence Data ,Radioimmunoassay ,Endogeny ,Cell Line ,chemistry.chemical_compound ,Phos ,Animals ,Humans ,Amino Acid Sequence ,Protein Precursors ,Aorta ,Cells, Cultured ,Pharmacology ,Endothelin-1 ,biology ,Endothelins ,Cell Membrane ,Phosphoramidon ,Glycopeptides ,biology.organism_classification ,Molecular biology ,Endothelin 1 ,Endothelial stem cell ,chemistry ,Cattle ,Endothelium, Vascular ,Cardiology and Cardiovascular Medicine ,Intracellular - Abstract
Several studies have shown that phosphoramidon (PHOS) reduces the release of endothelin-1 (ET-1) from cultured endothelial cells. Moreover, the main endothelin-converting enzyme (ECE) activity in these cells is a membrane-bound metallopeptidase that is also inhibited by PHOS. We have investigated further the role of the PHOS-sensitive ECE in the conversion of big ET-1 to ET-1. ET-1 was measured using a radioimmunoassay specific for the C-terminal ET[16-21] sequence. The effect of PHOS on the production of ET-1 from endogenous precursors was determined using cultured bovine aortic endothelial cells (BAECs) and the human endothelial cell line (EA.hy 926). The concentrations of ET-1 accumulating in the medium over 24 h from BAECs were lowered by PHOS (-27% 10 microM, -76% 100 microM). In contrast, with EA.hy 926 cells, the same concentrations of PHOS increased by five- to sixfold the amount of ET-1 present in the medium after 24-h incubation. In other experiments, incubation of big ET-1 (1 microM) with intact BAECs or EA.hy 926 cells resulted in the generation of ET-1, and with both cell types this was inhibited by PHOS (IC50: BAECs = 6.4 microM; EA.hy 926 = 0.26 microM). These results are consistent with both cell types having a PHOS-sensitive ECE that is readily accessible to exogenous big ET-1 and is therefore probably located on the plasma membrane. Furthermore, another intracellular ECE may play a part in the endogenous intracellular formation of ET-1 in EA.hy 926 cells.
- Published
- 1993
32. Conversion of glyceryl trinitrate to nitric oxide in tolerant and non-tolerant smooth muscle and endothelial cells
- Author
-
Alessandra Pistelli, Daniela Salvemini, and John R. Vane
- Subjects
Male ,medicine.medical_specialty ,Platelet Aggregation ,Endothelium ,Aorta, Thoracic ,In Vitro Techniques ,Nitric Oxide ,Muscle, Smooth, Vascular ,Sulfobromophthalein ,Nitric oxide ,Nitroglycerin ,chemistry.chemical_compound ,Internal medicine ,medicine ,Animals ,Humans ,Cyclic GMP ,Phenylephrine ,Nitrites ,Pharmacology ,Metyrapone ,Chemistry ,Proadifen ,Acetylcysteine ,Endocrinology ,medicine.anatomical_structure ,Cell culture ,cardiovascular system ,Platelet aggregation inhibitor ,Endothelium, Vascular ,Rabbits ,Sodium nitroprusside ,Platelet Aggregation Inhibitors ,Research Article ,circulatory and respiratory physiology ,medicine.drug - Abstract
1. Exposure of smooth muscle cells (SMC) to glyceryl trinitrate (GTN, 75-600 microM) for 30 min led to a concentration-dependent increase in nitrite (NO2-), one of the breakdown products of nitric oxide (NO). This was not affected by 30 min pretreatment of the cells with 0.5 mM of sulphobromophthalein (SBP) an inhibitor of glutathione-S-transferase (GST), by metyrapone or SKF-525A inhibitors of cytochrome P450. These experiments were confirmed by organ bath studies using rabbit aortic strips denuded of endothelium and contracted with phenylephrine. Thus, a 30 min incubation of the strips with 0.5 mM SPB, metyrapone or SKF-525A did not affect the relaxations in response to GTN (10(-10)-10(-6) M). 2. Potentiation of the anti-platelet effect of GTN (44 microM) by endothelial cells (EC, 40 x 10(3) cells) was not affected by prior incubation of EC with SBP, metyrapone or SKF-525A (all at 0.5 mM). 3. Potentiation of the antiplatelet activity of GTN (11-352 microM) by small numbers of SMC (24 x 10(3) cells) or EC (40 x 10(3) cells) treated with indomethacin (10 microM) was attenuated when the SMC or EC were treated in culture with a high concentration of GTN (600 microM) for 18 h beforehand (referred to as 'tolerant' cells). In addition, tolerant SMC produced far less NO2- than non-tolerant SMC. 4. Exposure of non-tolerant SMC or EC (10(5) cells) to GTN (200 microM) for 3 min increased (3-4 fold) the levels of guanosine 3':5'-cyclic monophosphate (cyclic GMP). This increase was much less (< I fold) in the tolerant SMC or EC (105 cells). The basal levels of cyclic GMP were similar in normal or tolerant SMC or EC. Sodium nitroprusside (80 JAM) or atrial natriuretic factor (ANF, I0- M) increased the levels of cyclic GMP in normal or tolerant SMC or EC to the same extent.5 The anti-platelet effects of GTN (44 JM) were potentiated by the sulphydryl donor N-acetylcysteine(NAC, 0.5mM). Incubation of GTN (150-1200fJM) for 30min with NAC (0.1-1mM) led to aconcentration-dependent increase in N02- formation. The reduced ability of tolerant SMC or EC to potentiate the anti-platelet activity of GTN was restored by NAC (0.5 mM). These anti-aggregatory effects were abolished by concurrent co-incubation with oxyhaemoglobin (10 JM) indicating that they were due to NO release.6 Thus, in SMC or EC, metabolism of GTN to NO does not depend on glutathione-S-transferase or the cytochrome P450 system. Furthermore, when compared to normal cells, tolerant SMC or EC metabolize GTN to NO less effectively as assessed by the reduced capacity to potentiate the antiplatelet effects of GTN, to release NO2- and to increase the level of cyclic GMP. This decrease in NO formation shows that tolerance to GTN is mainly due to impaired biotransformation of GTN to NO. NAC, by directly forming NO from GTN, compensates for this failing mechanism.
- Published
- 1993
33. Comparative Studies with the Endothelin Receptor Antagonists BQ-123 and PD 142893 Indicate At Least Three Endothelin Receptors
- Author
-
Timothy D. Warner, Roger Corder, John R. Vane, Graham H. Allcock, and Emma J. Mickley
- Subjects
Endothelin Receptor Antagonists ,Male ,medicine.medical_specialty ,Vasodilator Agents ,Guinea Pigs ,Molecular Sequence Data ,Aorta, Thoracic ,Viper Venoms ,In Vitro Techniques ,Peptide hormone ,Peptides, Cyclic ,Muscle, Smooth, Vascular ,chemistry.chemical_compound ,Internal medicine ,medicine.artery ,medicine ,Animals ,Thoracic aorta ,Amino Acid Sequence ,Rats, Wistar ,Receptor ,Pharmacology ,BQ-123 ,Chemistry ,Vas deferens ,Antagonist ,Muscle, Smooth ,Long-term potentiation ,Rats ,medicine.anatomical_structure ,Endocrinology ,cardiovascular system ,Rabbits ,Cardiology and Cardiovascular Medicine ,Endothelin receptor ,Oligopeptides - Abstract
Endothelin-1 (ET-1), endothelin-3 (ET-3), sarafotoxin 6b (SX6b), and sarafotoxin 6C (SX6c) were used as agonists, and BQ-123 (ETA-selective) and PD 142893 (ET receptor-nonselective) were used as antagonists to characterize the receptors mediating the effects of the ET/SX peptides on a variety of isolated smooth-muscle preparations. Contractions of the rat thoracic aorta, rat isolated perfused mesentery, and guinea pig ileum and potentiation of twitch of the rat vas deferens were mediated by ETA receptors in that they showed the order of potency ET-1 = SX6bET-3SX6C. These effects were antagonized by BQ-123 or PD 142893. Contractions of the rabbit pulmonary artery and rat stomach strip, inhibition of twitches in the guinea pig ileum, and vasodilatations of the rat isolated perfused mesentery showed the order of potency ET-1 = SX6b = ET-3 = SX6c and were unaffected by BQ-123, suggesting involvement of ETB receptors. However, in these tissues, PD 142893 antagonized only dilatations of the rat mesentery to ET-1 but not any of the other effects of ET-1. Thus, we suggest that there are three types of endothelin receptors: ETA and two subtypes of ETB.
- Published
- 1993
34. Evidence for Vesicles That Transport Endothelin-1 in Bovine Aortic Endothelial Cells
- Author
-
Erik Änggård, John R. Vane, Roger Corder, and Vanessa J. Harrison
- Subjects
Radioimmunoassay ,Endothelin-Converting Enzymes ,Peptide hormone ,Biology ,Centrifugation, Density Gradient ,Animals ,Aspartic Acid Endopeptidases ,Aorta ,Cells, Cultured ,Pharmacology ,Endothelins ,Vesicle ,Glycopeptides ,Metalloendopeptidases ,Secretory Vesicle ,Endothelin 1 ,Molecular biology ,Endothelial stem cell ,Biochemistry ,Cattle ,Endothelium, Vascular ,Ultracentrifuge ,Cardiology and Cardiovascular Medicine ,Intracellular ,Subcellular Fractions - Abstract
To facilitate studies of the intracellular processing of endothelin-1 (ET-1) in endothelial cells we developed an enrichment procedure for the isolation of transport or secretory vesicles containing ET-1. Cultured bovine aortic endothelial cells (BAECs) were disrupted using a tight-fitting Dounce homogenizer, and subcellular fractions were isolated by sucrose-density-gradient ultracentrifugation. ET-1 immunoreactivity (ET-IR) in the fractions was measured with a specific ET[16-21] radio-immunoassay (RIA). The major peak of ET-IR was consistently localized at the 1.0/1.2 M sucrose interface (10.96 fmol/10(6) cells) in each preparation of subcellular fractions. The mean level of ET-IR at this interface, expressed as a percentage of the total, was 47.9 +/- 3.5% (n = 6). This finding provides strong evidence for the existence of a vesicle that transports ET-1 within BAECs, which may be an important site for endogenous ET-1 processing. A number of studies have reported that the final processing step in ET-1 biosynthesis by the hypothetical endothelin-converting enzyme (ECE) is inhibited by phosphoramidon (PHOS). Therefore, levels of PHOS-sensitive ECE activity in each fraction were assessed in parallel with ET-IR levels. The ECE activity associated with the peak of ET-IR (2.67 pmol ET-1/h/10(6) cells) was insensitive to 100 microM PHOS. However, the peak of ECE-like activity (10.4 pmol ET-1/h/10(6) cells) localized in the 0.8 M sucrose band was inhibited by 79% in the presence of 100 microM PHOS.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1993
35. Control of the Circulation by Endothelial Mediators
- Author
-
John R. Vane
- Subjects
Vascular wall ,Pathology ,medicine.medical_specialty ,Endothelium ,business.industry ,Immunology ,General Medicine ,Anatomy ,medicine.anatomical_structure ,Circulation (fluid dynamics) ,Smooth muscle ,Immunology and Allergy ,Medicine ,business - Published
- 1993
36. Contents, Vol. 101, 1993
- Author
-
J. Sany, J. Clèdes, M. Dueymes, G.L. Asherson, J. Barrier, Hiroshi Nakajima, Oluseyi A. Vanderpuye, Takehiro Koshio, C. Jorgensen, L. Mjörnstedt, John A. McIntyre, M.C. Caroleo, L. Guillevin, J.C. Piette, K.L. Morgan, J.M. Roe, Kyung Hyo Kim, F. Dieli, D. Mottier, P. Youinou, Rob C. Aalberse, Ernst Gleichmann, V. Colizzi, J.M. Dueymes, Hideharu Endo, A. Bellavia, O. Meyer, H. Yilmaz, A. Lamour, P.Y. Hatron, Akio Yamada, Larry W. Williams, Mariam Al-Laith, K.Y. Chua, C. Series, Markus Uhrberg, M. Olausson, Ricki M. Helm, Carlos A. Labarrere, Koichi Ikizawa, Marjan van den Berg, D.A. Isenberg, C. Massot, Christina Stein, Wim van’t Hof, C. Conri, P.K. Kehal, Yukiyoshi Yanagihara, P. Galanaud, F.L. Pearce, A.A. Drosos, A.L. de Weck, Els van Vliet, R. Maran, B. Kjellson, Wesley Burks, Takao Shida, Dong Soo Kim, David E. Milne, Sho Yoshida, John R. Vane, J.F. Besancenot, B. Grobois, A. Salerno, Itsuo Iwamoto, L. Wramner, H.M. Moutsopoulos, M. Mattei, Keiichi Kajiwara, Peter C. Driedijk, M. Longy-Boursier, G. Dien, J. Jouquan, Richard J. Brenner, T. Söderström, Y. Shoenfeld, W.R. Thomas, P. Philippe, and P. Le Goff
- Subjects
business.industry ,Immunology ,Immunology and Allergy ,Medicine ,General Medicine ,business - Published
- 1993
37. Heterogeneous Receptors Mediate Endothelin-1-Induced Changes in Blood Pressure, Hematocrit, and Platelet Aggregation
- Author
-
Lorraine McMurdo, Roger Corder, Paul S. Lidbury, Christoph Thiemermann, and John R. Vane
- Subjects
Male ,medicine.medical_specialty ,Mean arterial pressure ,Indoles ,Platelet Aggregation ,Blood Pressure ,Prostacyclin ,In Vitro Techniques ,Hematocrit ,Internal medicine ,medicine ,Animals ,Receptor ,Pharmacology ,medicine.diagnostic_test ,Receptors, Endothelin ,Chemistry ,Endothelins ,Azepines ,Endothelin 1 ,Endocrinology ,Rabbits ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,Endothelin receptor ,Oligopeptides ,Vasoconstriction ,Ex vivo ,circulatory and respiratory physiology ,medicine.drug - Abstract
Using selective endothelin (ET) receptor antagonists, we investigated which ET receptor subtypes mediate the changes in blood pressure and hematocrit produced by intraarterial injection of ET-1 in the anesthetized rabbit. In addition, the receptor through which ET-1 stimulates the release of prostacyclin (PGI2) and, hence, inhibits ex vivo platelet aggregation, was identified. FR 139317 (ETA antagonist, 0.6 mg kg-1 min-1 preceded by a loading dose of 3 mg kg-1 i.v.) and PD 145065 (nonselective ETA/ETB antagonist, 0.6 mg kg-1 min-1 preceded by a loading dose of 3 mg kg-1 i.v.) attenuated the ET-1 (1 nmol kg-1 i.a.)-induced rise in mean arterial pressure (MAP) by 89% and 75%, respectively. In contrast to FR 139317, PD 145065 also abolished the initial, transient depressor response brought about by ET-1. ET-1 caused a significant increase in hematocrit 15 min after its injection. PD 145065 caused a significantly greater inhibition of this hemoconcentration than FR 139317. ET-1 inhibited ex vivo platelet aggregation by 96%, measured 5 min after injection of the peptide. PD 145065, but not FR 139317, abolished the antiaggregatory effects of ET-1. Thus, the ET-1-induced vasoconstriction in the anesthetized rabbit is predominantly mediated via the ETA receptor, whereas the depressor and antiaggregatory actions of ET-1 are caused by activation of the ETB receptor. Moreover, activation of both receptor subtypes by ET-1 accounts for the increase in hematocrit produced by ET-1 in vivo.
- Published
- 1993
38. NG-hydroxy-l-arginine and hydroxyguanidine potentiate the biological activity of endothelium-derived relaxing factor released from the rabbit aorta
- Author
-
Richard J. Gryglewski, Waldemar Radziszewski, Stefan Chłopicki, Artur Zembowicz, and John R. Vane
- Subjects
Male ,medicine.medical_specialty ,Endothelium ,Arginine ,Antimetabolites ,Biophysics ,Vasodilation ,In Vitro Techniques ,Hydroxylamines ,Nitric Oxide ,Guanidines ,Biochemistry ,Muscle, Smooth, Vascular ,chemistry.chemical_compound ,Internal medicine ,medicine ,Animals ,Molecular Biology ,Aorta ,Lagomorpha ,Dose-Response Relationship, Drug ,biology ,Endothelium-derived relaxing factor ,Substrate (chemistry) ,Drug Synergism ,Long-term potentiation ,Biological activity ,Cell Biology ,biology.organism_classification ,Acetylcholine ,Perfusion ,NG-Nitroarginine Methyl Ester ,medicine.anatomical_structure ,Endocrinology ,chemistry ,cardiovascular system ,Endothelium, Vascular ,Rabbits - Abstract
We investigated the effects of NG-hydroxy-L-arginine (L-HOArg) and hydroxyguanidine (HOG) on the synthesis and vasorelaxant activity of endothelium-derived relaxing factor (NO) released from the rabbit aortic endothelium. Both L-HOArg (10 microM) and HOG (10 microM) equally potentiated the vasorelaxant activity of NO released by Ach (0.1 or 0.3 microM) from the luminally perfused rabbit aorta and bioassayed using the superfused strips of the endothelium-denuded rabbit aorta. This potentiation was caused by the generation of a more stable vasodilator during the chemical reaction of L-HOArg or HOG with NO and it was abolished by NG-nitro-L-arginine methyl ester (L-NO2Arg, 10 microM). In contrast, in organ baths, L-HOArg (10 microM) or HOG (10 microM) did not affect the relaxations of intact rabbit aortic rings induced by Ach (0.01-1 microM). At concentrations higher than 10 microM, both L-HOArg and HOG were endothelium-independent vasorelaxants. However, L-HOArg (100 microM) prevented the inhibition by L-NO2Arg (10 microM) of Ach-induced relaxations of bathed aortic rings which indicates that L-HOArg is still a substrate for the NO synthase in the endothelium of the rabbit aorta.
- Published
- 1992
39. Potentiation of the vasorelaxant activity of nitric oxide by hydroxyguanidine: implications for the nature of endothelium-derived relaxing factor
- Author
-
Markus Hecker, John R. Vane, Tomasz A. Swierkosz, Artur Zembowicz, and Garry J. Southan
- Subjects
Arginine ,Endothelium ,Stereochemistry ,Muscle Relaxation ,Bradykinin ,Prostacyclin ,In Vitro Techniques ,Hydroxylamines ,Nitric Oxide ,Guanidines ,Muscle, Smooth, Vascular ,Nitric oxide ,chemistry.chemical_compound ,medicine ,Animals ,Aorta ,Cells, Cultured ,Chromatography, High Pressure Liquid ,Pharmacology ,biology ,Endothelium-derived relaxing factor ,Drug Synergism ,Epoprostenol ,Vasodilation ,Endothelial stem cell ,Nitric oxide synthase ,NG-Nitroarginine Methyl Ester ,medicine.anatomical_structure ,chemistry ,biology.protein ,Cattle ,Amino Acid Oxidoreductases ,Endothelium, Vascular ,Rabbits ,Nitric Oxide Synthase ,Research Article ,medicine.drug - Abstract
1. We recently demonstrated that NG-hydroxy-L-arginine (L-HOArg) is a substrate for the constitutive nitric oxide (NO) synthase present in bovine aortic endothelial cells cultured on microcarrier beads (EC). Furthermore, L-HOArg reacts chemically with NO released from these cells to form a potent and more stable vasodilator. This is most likely through a reaction with the hydroxyguanidino group. 2. Here, we studied the interaction of a simpler molecule, hydroxyguanidine (HOG) with NO. 3. HOG (10 microM), like L-HOArg (10 microM) or NG-hydroxy-D-arginine (D-HOArg, 10 microM), potentiated and stabilized the relaxant activity of authentic NO. 4. When NO was bubbled through the solution of HOG, a new compound was formed. It had similar physicochemical properties to those of the previously described L-HOArg/NO adduct. It was also a potent vasodilator and its action was inhibited by oxyhaemoglobin (10 microM), indicating formation of a NO-containing substance. 5. Moreover, HOG (10 microM) was not a substrate for the constitutive NO synthase present in the microsomal fraction of EC and did not affect the flow-induced or bradykinin-stimulated generation of prostacyclin, as measured by 6-keto-PGF1 alpha. 6. We also studied the effect of HOG on the endothelium-derived relaxing factor (EDRF) released from the column of EC. HOG (10 microM) potentiated and stabilized the relaxations of rabbit aortic strips induced by EDRF released by bradykinin (5-20 pmol) or ADP (5-10 nmol). These relaxations were inhibited by NG-nitro-L-arginine methyl ester (L-NAME, 10 microM) and L-arginine (L-Arg, 1 mM) reversed the inhibitory effects of L-NAME. 7. HOG (10 iM) augmented the basal (flow-induced) EC-dependent relaxations which were also inhibited by L-NAME (10 1M) and the effects of L-NOArg were reversed by L-Arg (1 mM).8. Thus, the hydroxyguanidino moiety of L-HOArg is involved in the reaction with NO. Moreover, the comparable reaction of the hydroxyguanidino compounds with NO on the one hand and with flowinduced and agonist-triggered EDRF on the other, strongly supports their common identity.
- Published
- 1992
40. NG-hydroxy-L-arginine prevents the haemodynamic effects of nitric oxide synthesis inhibition in the anaesthetized rat
- Author
-
John R. Vane, Claire E. Walder, and Christoph Thiemermann
- Subjects
Male ,medicine.medical_specialty ,Arginine ,Hemodynamics ,Blood Pressure ,Nitric Oxide ,Renal Circulation ,Nitric oxide ,chemistry.chemical_compound ,Internal medicine ,medicine ,Animals ,Rats, Wistar ,Pharmacology ,Kidney ,Renal circulation ,Endothelium-derived relaxing factor ,Rats ,NG-Nitroarginine Methyl Ester ,medicine.anatomical_structure ,Endocrinology ,chemistry ,Renal blood flow ,Vascular resistance ,Vascular Resistance ,Research Article - Abstract
1. We have investigated the effects of L-hydroxy-L-arginine (L-HOArg), an intermediate in the biosynthesis of nitric oxide (NO) from L-arginine (L-Arg), on the haemodynamic effects (systemic blood pressure and renal blood flow) of the NO synthesis inhibitor NG-nitro-L-arginine methyl ester (L-NAME) in the anaesthetized rat. 2. L-Arg or L-HOArg (3 mg kg-1 min-1), but not D-arginine (D-Arg) or NG-hydroxy-D-arginine (D-HOArg), elicited a slight but significant increase in total renal blood flow (RBF) of 11 +/- 2% and 11 +/- 1%. Since mean arterial blood pressure (MAP) did not change this dose of L-Arg or L-HOArg resulted in a reduced renal vascular resistance (RVR) of the same magnitude. 3. Bolus injections of L-NAME, at 0.3 or 1 mg kg-1 i.v., produced a significant fall in RBF of 11 +/- 2% and 32 +/- 5% and an increase in MAP of 7 +/- 3 mmHg and 22 +/- 5 mmHg, respectively. Consequently, RVR was elevated by 21 +/- 5% and 52 +/- 10%. 4. L-Arg or L-HOArg (3 mg kg-1 min-1) reduced the L-NAME-induced (0.3 or 1 mg kg-1) falls in RBF and increases in RVR by more than 65%. Neither D-Arg nor D-HOArg (3 mg kg-1 min-1) had any significant effect on the changes in RBF or RVR induced by L-NAME. 5. L-Arg or L-HOArg (3 mg kg-' min-') attenuated the pressor effect of L-NAME (3 mg kg-') by 73% and 64%, respectively, while neither the D-isomer of arginine nor hydroxyarginine had any effect.6. These results demonstrate that L-HOArg antagonizes the haemodynamic effects of NO-biosynthesis inhibition in vivo, thus supporting the hypothesis that L-HOArg is an intermediate in the formation of NO from L-Arg.
- Published
- 1992
41. Cultured astrocytoma cells generate a nitric oxide-like factor from endogenous L-arginine and glyceryl trinitrate: effect of E. coli lipopolysaccharide
- Author
-
Daniela Salvemini, Alessandra Pistelli, John R. Vane, Erik Änggård, and Vincenzo Mollace
- Subjects
Lipopolysaccharides ,Platelet Aggregation ,Lipopolysaccharide ,Arginine ,Indomethacin ,Astrocytoma ,Pharmacology ,Cycloheximide ,Nitric Oxide ,Nitric oxide ,Superoxide dismutase ,Nitroglycerin ,chemistry.chemical_compound ,Escherichia coli ,Tumor Cells, Cultured ,medicine ,Humans ,Platelet ,Cyclic GMP ,omega-N-Methylarginine ,biology ,Biochemistry ,chemistry ,Cell culture ,biology.protein ,Sodium nitroprusside ,Research Article ,medicine.drug - Abstract
1. The inhibitory activity of astrocytoma cells (0.25-3 x 10(5)) treated with indomethacin (10 microM) on platelet aggregation was enhanced by incubating the cells with E. coli lipopolysaccharide (LPS, 0.5 micrograms ml-1) for 18 h. This effect was attenuated when cycloheximide (10 micrograms ml-1) was incubated together with LPS. The inhibition of platelet aggregation by cells treated with LPS was potentiated by superoxide dismutase (60 u ml-1) and ablated by oxyhaemoglobin (oxyHb, 10 microM) or NG-monomethyl-L-arginine (L-NMMA, 30-300 microM). The effects of L-NMMA were reversed by co-incubation with L-arginine (L-Arg, 100 microM) but not D-arginine (D-Arg, 100 microM). LPS also increased the levels of nitrite in the culture media and this increase was ablated by co-incubation with L-NMMA (300 microM) or cycloheximide (10 micrograms ml-1). 2. Astrocytoma cells (0.5 x 10(5)) treated with indomethacin (10 microM) enhanced the platelet inhibitory activity of glyceryl trinitrate (GTN, 11-352 microM) but not that of sodium nitroprusside (4 microM). Furthermore, when incubated with GTN (200 microM) a 4 fold increase in the levels of guanosine 3':5'-cyclic monophosphate (cyclic GMP) was observed. These effects were abrogated by co-incubation with oxyHb (10 microM) but not with L-NMMA (300 microM). Treatment of the cells with LPS (0.5 micrograms ml-1) for 18 h did not enhance their capacity to form NO from GTN. 3. Thus, in cultured astrocytoma cells, LPS enhances the formation of nitric oxide from endogenous L-arginine.In addition, these cells can metabolize GTN to nitric oxide but this process is not enhanced by LPS stimulation.
- Published
- 1992
42. The two-step conversion of big endothelin 1 to endothelin 1 and degradation of endothelin 1 by subcellular fractions from human polymorphonuclear leukocytes
- Author
-
John R. Vane, Markus Hecker, and Semiko Kaw
- Subjects
Male ,medicine.hormone ,Metabolite ,In Vitro Techniques ,Muscle, Smooth, Vascular ,Endothelins ,chemistry.chemical_compound ,Cytosol ,Microsomes ,medicine ,Animals ,Humans ,Protease Inhibitors ,Protein Precursors ,Chromatography, High Pressure Liquid ,Serine protease ,Multidisciplinary ,Endothelin-1 ,biology ,Chemistry ,Cell Membrane ,Elastase ,hemic and immune systems ,Endothelin 1 ,Elastase inhibitor ,Biochemistry ,biology.protein ,Rabbits ,Jugular Veins ,PMSF ,Endothelin receptor ,Research Article ,Muscle Contraction ,Subcellular Fractions - Abstract
The metabolism of big endothelin 1 (bET) and endothelin 1 (ET-1) by subcellular fractions from human polymorphonuclear leukocytes (PMNs) was investigated by bioassay and reversed-phase high-performance liquid chromatography. More than 80% of endothelin-converting activity was recovered from the cytosolic fraction, which in addition to ET-1 generated other peptides from bET. The processing of bET to all its metabolites including ET-1 was prevented by the serine protease inhibitor 3,4-dichloroisocoumarin (DCI; 50 microM) or the elastase inhibitor ONO-5046 (100 microM) but not by phenylmethylsulfonyl fluoride (PMSF; 143 microM), another serine protease inhibitor. Paradoxically, human leukocyte elastase, despite generating a bET fragmentation pattern similar to that of PMN cytosol, produced very little ET-1. However, subsequent treatment of the elastase-derived metabolites of bET with PMN cytosol in the presence of ONO-5046 dramatically increased the amount of ET-1 formed. The generation of ET-1 following this intervention was inhibited by DCI. The PMN membrane preparation degraded ET-1 to a major metabolite, similar to that produced from ET-1 by elastase, and several minor products, paralleled by a loss of its smooth muscle contracting activity. The degradation of ET-1 by PMN microsomes was prevented by DCI, PMSF, or ONO-5046. Our results suggest that an elastase-initiated serine protease cascade is responsible for the sequential conversion of bET to ET-1 by the PMN cytosol. Elastase also partly accounts for the ET-metabolizing properties of PMN microsomes.
- Published
- 1992
43. The metabolism of glyceryl trinitrate to nitric oxide in the macrophage cell line J774 and its induction by Escherichia coli lipopolysaccharide
- Author
-
John R. Vane, Alessandra Pistelli, Erik Änggård, Vincenzo Mollace, and Daniela Salvemini
- Subjects
Lipopolysaccharides ,medicine.medical_specialty ,Hot Temperature ,Arginine ,Biology ,Cycloheximide ,Nitric Oxide ,Biochemistry ,Cell Line ,Nitric oxide ,Mice ,Nitroglycerin ,chemistry.chemical_compound ,Internal medicine ,Escherichia coli ,medicine ,Animals ,Humans ,Cyclic GMP ,Nitrites ,Pharmacology ,U937 cell ,Macrophages ,Drug Tolerance ,Macrophage Activation ,Molecular biology ,In vitro ,Endocrinology ,chemistry ,Cell culture ,Oxyhemoglobins ,cardiovascular system ,Microsome ,Amino Acid Oxidoreductases ,Sodium nitroprusside ,Nitric Oxide Synthase ,Platelet Aggregation Inhibitors ,circulatory and respiratory physiology ,medicine.drug - Abstract
The metabolism of glyceryl trinitrate (GTN) to nitric oxide (NO) was studied in the mouse macrophage cell line J774 and in the human monocytic cell line U937 in the absence or presence of Escherichia coli lipopolysaccharide (LPS). Two bioassay systems were used: inhibition of platelet aggregation and measurement of cGMP after stimulation by NO of guanylate cyclase in J774 cells. In addition, NO produced from GTN by cells or by cellular fractions was measured as nitrite (NO − 2 ) one of its breakdown products. J774 cells (1.25 × 10 5 cells) treated with indomethacin (10 μM) enhanced the platelet inhibitory activity of GTN (22-352 μM) but not that of sodium nitroprusside (4 μM). This effect was abrogated by co-incubation with oxyhaemoglobin (oxyHb, 10 μM) indicating release of NO from GTN. U937 cells (up to 60 × 10 5 ) did not metabolize GTN to NO. LPS (0.5 μg/mL for 18 hr) enhanced at least 2-fold the capacity of J774 cells but not that of U937 cells to form NO from GTN and this enhancement was attenuated when cycloheximide (10 μg/mL) was incubated together with LPS. In the absence of LPS stimulation, cycloheximide had no effect. Furthermore, when incubated with GTN (200 μM), J774 cells treated with LPS released more NO from GTN as indicated by a 3-fold greater increase in their level of cGMP which was prevented by oxyHb (10 μM). Incubation of J774 cells with GTN (75–600 μM) for 30 min led to a concentration-dependent increase in NO − 2 which was substantially reduced when the cells were boiled. The microsomal fraction was more potent than the cytosol in producing NO − 2 from GTN (1.2–2.4 mM). Release of NO − 2 from GTN by J774 cells was not affected by treating the cells with the NO synthase inhibitor, N G -monomethyl- l -arginine (MeArg, 300 μM). In J774 cells made tolerant to GTN, potentiation of the anti-platelet effects of GTN (11–352 μM) and release of NO − 2 from GTN was reduced. Thus, J774 cells but not U937 cells convert GTN to NO. This enzymic pathway (present mainly in the microsomal fraction of the J774 cells) is induced by LPS and is not regulated by endogenous NO released from L-Arg by the enzyme NO synthase. Furthermore, when compared to normal cells, tolerant J774 cells metabolize GTN to NO less effectively as assessed by a reduced capacity to potentiate the anti-platelet effect of GTN and to release NO − 2 . The presence of this enzyme system and its induction by LPS in cells other than smooth muscle cells and endothelial cells has therapeutic implications.
- Published
- 1992
44. Role of intracellular thiols in release of EDRF from cultured endothelial cells
- Author
-
William C. Sessa, Markus Hecker, I. Siegle, Heather Macarthur, and John R. Vane
- Subjects
Physiology ,Prostacyclin ,Arginine ,Nitric Oxide ,Nitroarginine ,Calcium in biology ,chemistry.chemical_compound ,Physiology (medical) ,medicine ,Animals ,Cysteine ,Sulfhydryl Compounds ,Aorta ,Cells, Cultured ,Diamide ,omega-N-Methylarginine ,Chemistry ,Ionomycin ,Sulfhydryl Reagents ,Endothelium-derived relaxing factor ,Glutathione ,Adenosine Diphosphate ,Endothelial stem cell ,Kinetics ,Biochemistry ,Ethylmaleimide ,cardiovascular system ,Biological Assay ,Cattle ,Arachidonic acid ,Endothelium, Vascular ,Cardiology and Cardiovascular Medicine ,Intracellular ,medicine.drug - Abstract
The availability of intracellular reduced thiols, such as L-cysteine or glutathione (GSH), may be critically important for the biosynthesis of endothelium-derived relaxing factor (EDRF). We have, therefore, investigated the effects of various sulfhydryl (SH) reagents, such as 1-chloro-2,4-dinitrobenzene (CDNB), diamide, 2,2'-dithiodipyridine (DTDP), or N-ethyl-maleimide (NEM), on the release of EDRF from cultured endothelial cells. None of the SH reagents tested affected the flow-induced EDRF release, but DTDP and NEM inhibited the release of EDRF stimulated by ADP, ionomycin, or poly-L-lysine. In contrast, NG-nitro-L-arginine methyl ester, an inhibitor of EDRF biosynthesis, blocked both the flow- and agonist-induced release of EDRF. Although NEM substantially potentiated the flow-induced release of prostacyclin (PGI2), probably due to a blockade of the reacylation of arachidonic acid, it inhibited the stimulated release of PGI2, whereas diamide did not significantly affect either release. Like CDNB or diamide, NEM, but not DTDP, caused a significant decrease in endothelial GSH. In contrast, both NEM and DTDP, but not CDNB or diamide, inhibited the ADP-induced mobilization of intracellular calcium, suggesting that they act on specific target proteins involved in endothelial cell calcium homeostasis rather than intracellular free SH groups. Moreover, the selective inhibition by these two SH reagents of the stimulated release of EDRF implies that a fundamental regulatory difference exists between agonist- and flow-induced EDRF biosynthesis.
- Published
- 1992
45. The actions of endothelins−1 and −3 on the vascular and capsular smooth muscle of the isolated blood perfused spleen of the dog
- Author
-
John R. Vane, P.G. Withrington, R. Croxton, G. De Nucci, and N. Ansari
- Subjects
medicine.hormone ,medicine.medical_specialty ,Spleen ,Vasodilation ,In Vitro Techniques ,Splenic artery ,Muscle, Smooth, Vascular ,Endothelins ,Norepinephrine ,Dogs ,Internal medicine ,medicine.artery ,medicine ,Animals ,Neuropeptide Y ,Vasoconstrictor Agents ,Pharmacology ,business.industry ,Muscle, Smooth ,Organ Size ,Anatomy ,Endothelin 1 ,Perfusion ,medicine.anatomical_structure ,Endocrinology ,Regional Blood Flow ,Vasoconstriction ,Vascular resistance ,medicine.symptom ,business ,Research Article - Abstract
1. Endothelin-1 (ET-1), endothelin-3 (ET-3) and noradrenaline (NA) were administered as intra-arterial bolus injections into the isolated, blood-perfused spleen of the dog to assess agonist properties and relative molar potencies on the vascular and capsular smooth muscle. 2. An initial small vasodilatation was observed occasionally at low doses (1.0-10 pmol) of ET-1. 3. ET-1, ET-3 and NA all caused graded increases in splenic arterial vascular resistance. The molar ED50 for the splenic vasoconstrictor response to ET-1 was significantly less (P less than 0.001) than that to ET-3; both peptides were significantly more potent as vasoconstrictor agents than NA. The maximum increase in splenic arterial vascular resistance was not significantly different for either ET-1, ET-3 or NA. 4. The time course of the splenic vasoconstrictor response to ET-1 was significantly (P less than 0.01) longer than that to equieffective doses of ET-3 or NA. 5. The splenic vasoconstrictor responses to ET-1 and ET-3 were accompanied by reductions in spleen volume. The rank order of molar potency in causing splenic capsular contraction was ET-1 greater than ET-3 greater than NA. The maximum reduction in splenic volume was significantly greater for NA than for either ET-1 or ET-3. The two peptides (ET-1, ET-3) were equiefficacious in contracting splenic capsular smooth muscle. 6. The high molar potency of ET-1 as a splenic arterial vasoconstrictor, over 1,700 times more potent than NA, suggests that it may play an important local role in the control of splenic haemodynamics.
- Published
- 1992
46. Metabolism of glyceryl trinitrate to nitric oxide by endothelial cells and smooth muscle cells and its induction by Escherichia coli lipopolysaccharide
- Author
-
Vincenzo Mollace, Erik Änggård, John R. Vane, Alessandra Pistelli, and Daniela Salvemini
- Subjects
Lipopolysaccharides ,medicine.medical_specialty ,Platelet Aggregation ,Endothelium ,Arginine ,medicine.medical_treatment ,Intraperitoneal injection ,Blood Pressure ,In Vitro Techniques ,Nitric Oxide ,Muscle, Smooth, Vascular ,Nitric oxide ,Nitroglycerin ,chemistry.chemical_compound ,Internal medicine ,Escherichia coli ,medicine ,Animals ,Humans ,Cycloheximide ,Cyclic GMP ,Cells, Cultured ,Nitrites ,omega-N-Methylarginine ,Multidisciplinary ,Chemistry ,Hemodynamics ,Rats ,Endothelial stem cell ,medicine.anatomical_structure ,Endocrinology ,cardiovascular system ,Omega-N-Methylarginine ,Platelet aggregation inhibitor ,Cattle ,Endothelium, Vascular ,Sodium nitroprusside ,Platelet Aggregation Inhibitors ,Research Article ,circulatory and respiratory physiology ,medicine.drug - Abstract
Here, we demonstrate that the metabolism of glyceryl trinitrate (GTN) to nitric oxide (NO) occurs not only in bovine aortic smooth muscle cells (SMCs) but also in endothelial cells (ECs) and that this biotransformation is enhanced by pretreatment with Escherichia coli lipopolysaccharide (LPS). Two bioassay systems were used: inhibition of platelet aggregation and measurement of cGMP after stimulation by NO of guanylate cyclase in SMCs or ECs. In addition, NO produced from GTN by cells was measured as nitrite (NO2-), one of its breakdown products. Indomethacin (10 microM)-treated SMCs or ECs enhanced the platelet inhibitory activity of GTN. This effect was abrogated by coincubation with oxyhemoglobin (oxyHb; 10 microM), indicating release of NO from GTN. LPS (0.5 microgram/ml; 18 h) enhanced at least 2- to 3-fold the capacity of SMCs or ECs to form NO from GTN, and this enhancement was attenuated when cycloheximide (10 micrograms/ml) was incubated together with LPS. Furthermore, when incubated with GTN (200 microM) SMCs or ECs treated with LPS (0.5 microgram/ml; 18 h) released more NO from GTN than nontreated cells as indicated by a much higher (8- to 9-fold) increase in the levels of cGMP. Exposure of SMCs to GTN (600 microM) for 30 min led to an increase in the levels of NO2- dependent on cell numbers, which was enhanced when SMCs were treated with LPS. Incubation of nontreated or LPS-treated cells with NG-monomethyl-L-arginine (300 microM; 60 min) did not influence the metabolism of GTN to NO. SMCs failed to enhance the antiplatelet activity of sodium nitroprusside. Anesthetized rats treated with an intraperitoneal injection of LPS (20 mg/kg) 18 h beforehand showed enhanced hypotensive responses to GTN (0.25-1 mg/kg). These effects were blocked by methylene blue (10 mg/kg) but not by indomethacin (3 mg/kg). LPS did not alter the hypotensive responses induced by phentolamine, verapamil, or SIN-1. Thus, both in vitro and in vivo, LPS induces the enzyme(s) metabolizing GTN to NO.
- Published
- 1992
47. The future of NSAID therapy: selective COX‐2 inhibitors
- Author
-
John R Vane and Regina M Botting
- Subjects
General Medicine - Published
- 2000
48. Brazilian viper and BP. control. Stamps issued on kidneys and hypertension--Uganda, 1978; John R Vane--Micronesia 2001 and Bothrops jararaca viper--Brazil, 2001
- Author
-
J V, Pai-Dhungat and John R, Vane
- Subjects
Hypertension, Renal ,Famous Persons ,Animals ,Humans ,Bothrops ,History, 19th Century ,Uganda ,Viper Venoms ,Kidney ,Philately ,Brazil - Published
- 2009
49. Studies on the importance of the proposed release of nitric oxide from platelets
- Author
-
Daniela Salvemini, Vincenzo Mollace, and John R. Vane
- Subjects
Blood Platelets ,Platelet Aggregation ,Arginine ,Pharmacology ,Nitric Oxide ,Inhibitory postsynaptic potential ,Nitric oxide ,Nitroglycerin ,chemistry.chemical_compound ,Thrombin ,medicine ,Humans ,Platelet ,Iloprost ,Incubation ,omega-N-Methylarginine ,Chemistry ,Biological activity ,Hematology ,Biochemistry ,cardiovascular system ,Collagen ,Platelet Aggregation Inhibitors ,circulatory and respiratory physiology ,medicine.drug - Abstract
The importance of the presence of the L-arginine (L-Arg)-nitric oxide (NO) pathway in platelet function was investigated. This was achieved by studying the interactions between anti-platelet agents such as glyceryl trinitrate (GTN) or iloprost (Ilo) and the NO precursor L-Arg. Thrombin or collagen-induced aggregation of human washed platelets was inhibited in a concentration-dependent fashion by a 3 min incubation with GTN (40-200 microM). This effect was reversed by oxyhaemoglobin (oxyHb, 10 microM). GTN at the lowest concentration tested (40 microM) potentiated the anti-aggregatory activity of subthreshold concentrations of Ilo (0.2 nM). GTN did not potentiate the action of L-arginine (100 microM) and L-Arg by itself failed to influence thrombin or collagen-induced platelet aggregation. The platelet responses to thrombin or collagen were not affected by a 3 min or 1 h treatment with the NO synthesis inhibitor NG-monomethyl-L-arginine (MeArg, 300 microM). This treatment did not alter the platelet inhibitory effects of GTN and in the presence of MeArg, exogenously applied L-Arg did not potentiate the anti-platelet activity of GTN. These results indicate that under our experimental conditions human washed platelets do not generate sufficient amounts of NO to modify (1) platelet aggregation or (2) the anti-platelet activity of GTN or iloprost.
- Published
- 1991
50. Nitric oxide from vascular smooth muscle cells: regulation of platelet reactivity and smooth muscle cell guanylate cyclase
- Author
-
Erik Änggård, John R. Vane, Daniela Salvemini, and Vincenzo Mollace
- Subjects
Blood Platelets ,Lipopolysaccharides ,medicine.medical_specialty ,Vascular smooth muscle ,Guanosine ,In Vitro Techniques ,Cycloheximide ,Arginine ,Nitric Oxide ,Monocytes ,Muscle, Smooth, Vascular ,Nitric oxide ,Mice ,Nitroglycerin ,chemistry.chemical_compound ,1-Methyl-3-isobutylxanthine ,Internal medicine ,Escherichia coli ,medicine ,Animals ,Humans ,Platelet ,Cyclic GMP ,Pharmacology ,omega-N-Methylarginine ,Superoxide Dismutase ,Macrophages ,Endothelium-derived relaxing factor ,Thrombin ,Muscle, Smooth ,Adenosine ,Endocrinology ,chemistry ,Guanylate Cyclase ,cardiovascular system ,Omega-N-Methylarginine ,Cattle ,Atrial Natriuretic Factor ,Research Article ,medicine.drug - Abstract
1. Incubation of smooth muscle cells (SMC) from bovine aorta for 3 min with human washed platelets treated with indomethacin (10 microM) promoted a cell number-related inhibition of platelet aggregation induced by thrombin (40 mu ml-1). This inhibition was not attributable to products of the cyclo-oxygenase pathway for the SMC were also treated with indomethacin (10 microM). 2. The inhibitory activity of the SMC on platelet aggregation was enhanced by incubating the SMC with E. coli lipopolysaccharide (LPS, 0.5 micrograms ml-1) for a period of 9 to 24 h. This effect was attenuated when cycloheximide (10 micrograms ml-1) was incubated together with LPS. Cycloheximide did not prevent the inhibitory activity of the non-treated cells. 3. The inhibition of platelet aggregation obtained with non-treated or LPS-treated SMC was potentiated by superoxide dismutase (SOD, 60 u ml-1) and ablated by oxyhaemoglobin (OxyHb, 10 microM). Preincubation of the SMC with NG-monomethyl-L-arginine (L-NMMA, 30-300 microM) for 60 min prevented their antiaggregatory activity. This effect was reversed by concurrent incubation with L-arginine (L-Arg, 100 microM) but not with D-arginine (D-Arg, 100 microM). 4. Exposure of the non-treated SMC (5 x 10(5) cells) to stirring (1000 r.p.m., 37 degrees C) for 10 min led to a significant increase in their levels of guanosine 3':5'-cyclic monophosphate (cyclic GMP) but not adenosine 3':5'-cyclic monophosphate (cyclic AMP). L-NMMA (300 microM) attenuated the increase in cyclic GMP induced by stirring but did not affect the basal levels of cyclic GMP in the cells.5. These findings support the idea that non-treated or LPS-treated cultured SMC can produce an NO-like factor. Production by the latter requires protein synthesis as evidenced by blockade with cycloheximide. This NO-like factor may play a role in the auto-regulation of smooth muscle cell reactivity through a cyclic GMP-dependent mechanism.
- Published
- 1991
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.